

SCREENING FOR ANTI-CANCER COMPOUNDS USING NETRIN-1 ACTIVITY

The subject matter of the present invention relates to an *in vitro* method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of metastatic cancer such as breast cancer, related to the overexpression of netrin-1 by the tumor cells.

Netrin-1, a diffusible laminin-related protein, has been shown to play a major role in the control of neuronal navigation during the development of the nervous system³¹, by interacting with its main receptors, DCC (Deleted in Colorectal Cancer)^{1,2,3} and UNC5H^{4,5}. However, more recently, netrin-1 has emerged as a completely different molecule that regulates cell survival. Indeed, the netrin-1 receptors DCC and UNC5H, -i.e., UNC5H1, UNC5H2, and UNC5H3- belong to the so-called dependence receptor family^{6,7}. Dependence receptors form a group of receptors that share the ability to induce cell death when expressed in settings in which their ligand is not available⁴⁴. Such receptors, which also include RET⁸, β -integrins⁹, Patched¹⁰, neogenin¹¹, p75^{NTR}¹² and the androgen receptor⁴⁰, share the functional property of inducing cell death when disengaged from their ligands, while the presence of their ligand blocks this pro-apoptotic activity. Such receptors thus create cellular states of dependence on their respective ligands^{13,14}.

This dependence effect has been suggested to act as a mechanism for eliminating tumor cells that would develop in settings of ligand unavailability: proliferation of tumor cells in a cell environment with constant and limited ligand presence or migration of metastatic tumor cells towards tissues where the ligand is not expressed. A selective advantage for a tumor cell would then be to lose the pro-apoptotic activity of its dependence receptors. It was predicted from genetic screens that the *C. elegans* netrin-1 -UNC6- interacted with UNC40 and with UNC5⁴². Four orthologues of UNC5 were identified in

mammals: UNC5H1, H2, H3, H4 and UNC40 was found to be the orthologue of the vertebrate DCC (Deleted in Colorectal Cancer)³⁹. Along this line, DCC was proposed in the early 1990s to be a tumor suppressor gene, whose expression is lost in the vast majority of human cancers^{15, 16}. This hypothesis also fits with the recent observation that UNC5H
 5 genes are down-regulated in the vast majority of colorectal tumors, hence suggesting that the loss of UNC5H genes represents a selective advantage for tumor development¹⁷. Interestingly, in mice, both inactivation of UNC5H3 and overexpression of netrin-1 in the gastro-intestinal tract are associated with intestinal tumor progression^{18, 19}, hence demonstrating *per se* that the loss of netrin-1 dependence receptors in the human pathology
 10 is a causal factor for tumor progression. However, although an initial series of reports supported the fact that DCC acted as a tumor suppressor (for a review see²⁹), doubts have arisen, mainly because of the rarity of point mutations in the DCC coding sequence and because of the lack of tumor predisposition in DCC hemizygous mice⁴¹.

However, the model described above predicts that both loss of the netrin-1 receptors
 15 and gain of ligand expression -i.e., autocrine expression- should be observed in human cancers, as they should represent similar selective advantages. This question is important not only for basic knowledge, but is crucial for therapy: indeed, inhibiting the extracellular interaction between netrin-1 dependence receptors and netrin-1 could represent an appealing strategy to trigger tumor regression.

20 It is particular desirable to provide simple and consistent means for identifying and characterizing new compounds which can be used for the treatment of cancer.

Surprisingly, the inventors have first demonstrated that, rather than losing netrin-1 dependence receptors, the majority of metastatic breast tumors show increased netrin-1 expression, a trait that may be used in therapy to trigger death of metastatic tumor.

25 If the pro-apoptotic signaling of DCC and/or UNC5H is beginning to be documented, an important question in this death/life signature dictated by DCC, UNC5H and more generally by the other known dependence receptors, is how does the presence of the ligand inhibit their pro-apoptotic activity⁵⁰.

In a second time, the inventors have analyzed whether netrin-1 induced DCC and/or
 30 UNC5H multimerization could be the critical step that inhibits DCC and/or UNC5H pro-apoptotic activity. Surprisingly, they have demonstrated that netrin-1 receptor, such as DCC

and/or UNC5H multimerizes in response to netrin-1, a process sufficient to inhibit apoptosis.

In a first aspect, the present invention is directed to an *in vitro* method for selecting a compound for the prevention or the treatment of cancer, wherein said method comprises the following steps of:

a) having a medium containing netrin-1, or a fragment thereof, and a netrin-1 receptor, or a fragment thereof, wherein:

- said netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, is able to specifically interact together to form a binding pair, and/or

- said netrin-1, or a fragment thereof, is able to induce the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, particularly the intracellular domain of said netrin-1 receptor;

b) contacting said medium with the compound to be tested;

c) - measuring the inhibition of the interaction between netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, and/or

- determine whether said compound inhibit the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, particularly the dimerization of the intracellular domain of said netrin-1 receptor; and

d) selecting said compound if:

- the measuring in step c) demonstrates a significantly inhibition of the interaction between netrin-1, or a fragment thereof, and netrin-1 receptor, or a fragment thereof, in presence of said compound, and/or

- the determination in step c) demonstrates a significantly inhibition of the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, in presence of said compound, particularly the dimerization of the intracellular domain of said netrin-1 receptor.

By the terms interaction between netrin-1 and its netrin-1 receptor, it is intended to designate in the present application the interaction which result to the selective advantage for tumor cells to escape netrin-1 dependence receptors induced apoptosis, preferably due to elevated netrin-1 level.

So, the inhibition of this interaction can be obtained for example by the complete or partial inhibition of the binding of netrin-1 to its receptor, notably in presence of a competitive ligand (such as an antibody which is directed to this extracellular membrane domain of said netrin-1 receptor), or in presence of a compound able to form a specific
 5 complex with the netrin-1 (such as a soluble extracellular membrane domain of its netrin-1 receptor, or part thereof).

In a preferred embodiment, the method according to the present invention is characterized in that said cancer to be prevent or treated is a cancer wherein tumoral cells express or overexpress netrin-1.

10 In another preferred embodiment, the method according to the present invention is characterized in that said cancer to be prevent or treated is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma, uterus adenocarcinoma, stomach adenocarcinoma, kidney
 15 adenocarcinoma and rectal adenocarcinoma.

In another preferred embodiment, the method according to the present invention is characterized in that said cancer to be prevent or treated is a metastatic or an aggressive cancer.

In the method according to the invention, said netrin-1 receptor is preferably
 20 selected from the group of DCC, UNC5H (particularly UNC5H1, UNC5H2 and UNC5H3), neogenin and the adenosine A2b, more preferably selected from the group of DCC, UNC5H1, UNC5H2 and UNC5H3.

In another preferred embodiment, the method according to the present invention is characterized in that at step a):

- 25 - said netrin-1 receptor fragment comprises or is the extracellular domain of the netrin-1 receptor, or part thereof able to interact with netrin-1; and/or
- said netrin-1 receptor fragment comprises or is the intracellular domain of the netrin-1 receptor, or part thereof able to dimerize or multimerize in presence of netrin-1.

In another preferred embodiment, the method according to the present invention is
 30 characterized in that said netrin-1 or/and said netrin-1 receptor are from mammal, particularly from mouse, rat or human.

In a particular aspect of the method of the present invention, at step a) said netrin-1 is from chicken.

In another preferred embodiment, the method according to the present invention is characterized in that said netrin-1 or/and said netrin-1 receptor and/or the compound to be tested is labelled by a marker able to be directly or indirectly measured.

In another preferred embodiment, the method according to the present invention is characterized in that at step c):

- the measure of the inhibition of the interaction between netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, is carried out by immunoassay (particularly by ELISA or by Immunoradiometric Assay (IRMA)), by Scintillation Proximity Assay (SPA) or by Fluorescence Resonance Energy Transfer (FRET); and/or
- the dimerization or multimerization, or its inhibition, of said netrin-1 receptor, or fragment thereof, particularly the intracellular domain, is carried out by immunoprecipitation or FRET.

In another particular preferred embodiment, the method according to the present invention is characterized in that at step a) said medium contains cells which express at their surface membrane an endogenous or a recombinant netrin-1 receptor, particularly a recombinant extracellular domain of said netrin-1 receptor.

In a preferred embodiment, said recombinant netrin-1 receptor also comprises the intracellular domain of said netrin-1 receptor.

In another particular preferred embodiment, the method according to the present invention is characterized in that at step a) said medium contains tumoral cells, preferably metastatic tumoral cells, which express endogenously said netrin-1 receptor at their membrane surface and which express or overexpress netrin-1, and wherein at step c) the inhibition of the interaction between netrin-1 and its netrin-1 receptor in presence of the compound to be tested, is measured by the apoptosis or cells death induced by the presence of the compound to be tested, preferably analysed using the trypan blue staining method as indicated in the examples below.

In a preferred embodiment said tumoral cells are selected from the group consisting of 4T1 cells, CAL51 cells, T47D cells, SKBR7 cells, IMR32 cells, GL26 cells and H358

cells, notably CAL51 cell lines, such as CAL51-36 cell line, which are much more susceptible to cell death in response to the presence of DCC-EC-Fc.

The present invention is also directed to an *in vitro* method for selecting a compound for the prevention or the treatment of cancer, wherein said method comprises the following steps of:

- a) having a medium containing a mammal cell expressing an endogenous or a recombinant netrin-1 receptor, or a fragment thereof comprising at least its intracellular domain, preferably a tumor cell, more preferably a cell presenting dimerization or multimerization of its netrin-1 receptor intracellular domain or a cell wherein its netrin-1 receptor intracellular domain is able to dimerize or multimerize in presence of netrin-1;
- b) contacting said medium with the compound to be tested, optionally the medium further containing netrin-1, or a fragment thereof able to interact with the extracellular domain of the netrin-1 receptor;
- c) determine whether the dimerization or multimerization of said netrin-1 receptor intracellular domain is inhibited in presence of said compound to be tested;
- d) optionally, determine (for example by the blue trypan method) whether the presence of the compound to be tested induces the cell death of said mammal cell; and
- e) selecting said compound if the determination in step c) demonstrates a significantly inhibition of the dimerization or multimerization of the intracellular domain of said netrin-1 receptor and/or if the determination in step d) demonstrates the cell death of said mammal cell.

In a second aspect, the present invention is directed to an *in vitro* method for predicting the presence of a metastatic cancer or an aggressive cancer (such as neuroblastoma) in a patient having a primary tumor from a biopsy of said patient containing primary tumors cells, said method comprising the following step of:

- (a) measuring of the netrin-1 expression level in said biopsy.

In a preferred embodiment, the method for predicting according to the present invention is characterized in that at step a) wherein an increase of the netrin-1 expression level in said biopsy, compared with expression of netrin-1 in non-metastatic primary tumor biopsies or in non-aggressive cancer biopsies is significant of the presence of a metastatic cancer or an aggressive cancer.

In a more preferred embodiment, the method for predicting according to the present invention is characterized in that a ratio superior to 2, preferably to 2.5, to 3, to 3.5, to 4, to 4.5 and to 5, between netrin-1 expression in the biopsy to be tested and in the non-metastatic or non-aggressive reference biopsy is significant of the presence of a metastatic or an aggressive cancer.

In a third aspect, the present invention is directed to an method for determining *in vitro* the efficiency of an anti-cancer treatment for a patient or for selecting patients who responds to a specific anti-cancer treatment, said method comprising the following step of:

(a) obtaining a primary tumor biopsy of said treated patient; and

(b) measuring of the netrin-1 expression level in said biopsy,

wherein the efficiency of said anti-cancer treatment is correlated with the decrease of the amount of the netrin-1 expression level measured in said biopsy, or

wherein the selected patients who respond to a specific anti-cancer treatment are patients where the amount of the netrin-1 expression level measured in their biopsy has been decreased after said specific treatment.

In a preferred embodiment, the method for determining *in vitro* the efficiency of an anti-cancer treatment for a patient or for selecting patients who responds to a specific anti-cancer treatment, is characterized in that said cancer induced an overexpression of netrin-1 and/or is a metastatic or an aggressive cancer.

In a preferred embodiment, the method for prediction or for determining *in vitro* the efficiency of an anti-cancer treatment for a patient is characterized in that the measured netrin-1 expression product is the RNA encoding netrin-1, particularly measured by a quantitative real time reverse PCR method, or in that the expression level of netrin-1 which is measured is the measure of the netrin-1 protein level, particularly by a method using specific antibodies able to specifically recognize said netrin-1 protein.

In a preferred embodiment, the method for prediction or for determining *in vitro* the efficiency of an anti-cancer treatment for a patient is characterized in that the primary tumor is a primary tumor of a cancer selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma,

uterus adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal adenocarcinoma.

In another aspect, the present invention is directed to a kit for the selection of a compound for the prevention or the treatment of cancer, wherein said kit comprises:

- 5 - a netrin-1 receptor protein, or a fragment thereof able to specifically interact with the netrin-1 protein to form a binding pair, preferably recombinant protein; and
- netrin-1 protein, or a fragment thereof able to specifically interact with said netrin-1 receptor protein to form a binding pair, preferably recombinant protein.

Said netrin-1 receptor being also preferably selected from the group of DCC,
 10 UNC5H (particularly UNC5H1, UNC5H2 and UNC5H3), neogenin and the adenosine A2b, more preferably selected from the group of DCC, UNC5H1, UNC5H2 and UNC5H3, more preferably from mammal such as from mouse, rat or human.

In a preferred embodiment, said kit comprises:

- tumoral cells which express netrin-1 receptor and which express or overexpress
- 15 netrin-1, particularly cells from metastatic tumoral cell line, preferably selected from the group consisting of 4T1 cells, CAL51 cells, T47D cells, SKBR7 cells, IMR32 cells, GL26 cells and H358 cells, notably CAL51 cell lines, such as CAL51-36 cell line, which are much more susceptible to cell death in response to the presence of DCC-EC-Fc.

In another aspect, the present invention comprises a compound selected from the
 20 group consisting of:

- a compound comprising an extracellular domain of netrin-1 receptor or fragment thereof able to specifically inhibit the interaction between the netrin-1 and said netrin-1 receptor, and/or able to inhibit the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, particularly to inhibit the intracellular domain of said netrin-1
- 25 receptor; and
- a monoclonal or polyclonal antibody directed specifically against netrin-1 or netrin-1 receptor, particularly directed to the extracellular domain of said netrin-1 receptor or to the netrin-1 fragment able to interact with the extracellular domain of said netrin-1 receptor,
- 30 as a medicament.

The amino acid sequence of human netrin-1 or human netrin receptor such as UNC5H1, UNC5H2 and UNC5H3 (Unc-5 homolog 1, 2 and 3 equivalent to Unc-5 homolog A, B and C) are well known by the skilled man. Example of these amino acid sequences with the localization of their particular domain can be found in Genbank under
5 the accession number AAD09221 or NP_004813 for human netrin-1, NP_588610 for human netrin receptor Unc-5 homolog 1, Q8IZJ1 for netrin receptor Unc-5 homolog 2 and O95185 for Unc-5 homolog 3.

Preferably, in the compounds of the present invention, said extracellular domain of netrin-1 receptor or fragment thereof is selected from the group of DCC, UNC5H
10 (particularly UNC5H1, UNC5H2 and UNC5H3), neogenin and the adenosine A2b, more preferably selected from the group of DCC, UNC5H1, UNC5H2 and UNC5H3, more preferably from mammal such as from mouse, rat or human.

In a more preferred embodiment, said compound according to the present invention comprises an extracellular domain of netrin-1 receptor from DCC, preferably said
15 compound is DCC-EC-Fc or DCC-5Fbn.

In another aspect, the present invention pertains to the use of the level of netrin-1 expression as a marker for the identification of metastatic cancer in a patient, preferably of metastatic breast or colorectal cancer, the most preferred being the metastatic breast cancer.

In another aspect, the present invention pertains to a method of treatment for
20 inducing the apoptosis or the cell death of tumor cells which have acquired the selective advantage to escape netrin-1 dependence receptors induced apoptosis, preferably by elevated netrin-1 level, in a patient comprising administering a compound able to inhibit the interaction between netrin-1 and its netrin-1 receptor, a compound able to inhibit the dimerization or the multimerization of the netrin-1 receptor, a compound according to the
25 present invention, or selected by the method of the present invention, in said patient in need thereof.

In another aspect, the present invention pertains to a method for the prevention or for the treatment of cancer in a patient comprising administering a compound according to the present invention, or selected by the method of the present invention, in said patient in
30 need thereof.

The present invention also comprises the use of a compound according to the present invention, or selected by the method of the present invention, for the manufacture of a medicament for the prevention or the treatment of cancer in mammals, including man. Preferably said cancer is a metastatic or an aggressive cancer.

5 More preferably, in the method of treatment or in the use of a compound according to the present invention, said cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma, uterus adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal
10 adenocarcinoma.

More preferably, in the method of treatment or in the use of a compound according to the present invention, the primary tumor cells of said cancer express or overexpress netrin-1.

The term "antibody" as used herein refers to immunoglobulin molecules and
15 immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) the netrin-1 protein or its receptor.

The term "antibody" comprises monoclonal or polyclonal antibodies but also chimeric or humanized antibodies.

20 An isolated netrin-1 protein or netrin-1 receptor protein, or a specific fragment thereof can be used as an immunogen to generate antibodies that bind such protein using standard techniques for polyclonal and monoclonal antibody preparation. It may be also possible to use any fragment of these protein which contains at least one antigenic determinant may be used to generate these specific antibodies.

25 A protein immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain said protein, or fragment thereof, and further can include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent.

30 Thus, antibody for use in accordance with the invention include either polyclonal, monoclonal chimeric or humanized antibodies. antibodies able to selectively bind, or which

selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 8 to 10 amino acids of an amino acid sequence of the netrin-1 protein or its receptor.

A preferred agent for detecting and quantifying mRNA or cDNA encoding netrin-1 protein, is a labeled nucleic acid probe or primers able to hybridize this mRNA or cDNA.

5 The nucleic acid probe can be an oligonucleotide of at least 10, 15, 30, 50 or 100 nucleotides in length and sufficient to specifically hybridize under stringent conditions to the mRNA or cDNA. The nucleic acid primer can be an oligonucleotide of at least 10, 15 or 20 nucleotides in length and sufficient to specifically hybridize under stringent conditions to the mRNA or cDNA, or complementary sequence thereof.

10 A preferred agent for detecting and quantifying the netrin-1 protein, is an antibody able to bind specifically to this protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by
15 coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

20 For example, in vitro techniques for detection of candidate mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of the candidate protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of candidate cDNA include Southern hybridizations.

25 When the invention encompasses kits for quantifying the level of netrin-1 protein, the kit can comprise a labeled compound or agent capable of quantifying these proteins. Said agents can be packaged in a suitable container. The kit can further comprise instructions for using the kit to quantify the level of the netrin-1 protein or of the netrin-1 transcript.

30 In certain embodiments of the method of the present invention, the determination of the netrin-1 transcripts involves the use of a probe/primer in a polymerase chain reaction

(PCR), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., 1988, Science 241:23-1080; and Nakazawa et al., 1994, Proc. Natl. Acad. Sci. USA, 91:360-364), or alternatively quantitative real time RT-PCR. This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g. mRNA) from the cells of the sample, optionally transforming mRNA into corresponding cDNA, contacting the nucleic acid sample with one or more primers which specifically hybridize to the netrin-1 or mRNA or their corresponding cDNA under conditions such that hybridization and amplification of the netrin-1 mRNA or cDNA occurs, and quantifying the presence of the amplification products. It is anticipated that PCR and/or LCR may be desirable to use as an amplification step in conjunction with any of the techniques used for quantifying nucleic acid detecting.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or set of primer or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to follow-up or diagnose patients.

Finally, the present invention is related to the use of antisense or iRNA (interfering RNA) oligonucleotides specific of the nucleic acid encoding netrin-1 protein for the manufacture of a medicament intended to prevent or to treat metastatic or aggressive cancer, preferably said cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma, pancreatic adenocarcinoma, uterus adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal adenocarcinoma.

Interfering RNA (iRNA) is a phenomenon in which a double stranded RNA (dsRNA) specifically suppresses the expression of a gene bearing its complementary sequence. iRNA has since become a useful research tool for many organisms. Although the mechanism by which dsRNA suppresses gene expression is not entirely understood, experimental data provide important insights. This technology has great potential as a tool to study gene function in mammalian cells and may lead to the development of pharmacological agents based upon siRNA (small interfering RNA).

When administered to a patient, a compound of the present invention is preferably administered as component of a composition that optionally comprises a pharmaceutically acceptable vehicle. The composition can be administered orally, or by any other convenient route, and may be administered together with another biologically active agent.

5 Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the selected compound of the present invention or pharmaceutically acceptable salts thereof.

Methods of administration include but are not limited to intradermal, intramuscular, 10 intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of the compound into the bloodstream or directly in the primary tumor.

15 Compositions comprising the compound according to the invention or selected by the methods according to the present invention, form also part of the present invention. These compositions can additionally comprise a suitable amount of a pharmaceutically acceptable vehicle so as to provide the form for proper administration to the patient. The term "pharmaceutically acceptable" means approved by a regulatory agency or listed by a 20 national or a recognized pharmacopeia for use in animals, mammals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical 25 vehicles can be saline, gelatin, starch and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, sodium stearate, glycerol monostearate, sodium chloride, 30 dried skim milk, glycerol, propylene, glycol, water and the like. Test compound compositions, if desired, can also contain minor amounts of wetting or emulsifying agents,

or pH buffering agents. The compositions of the invention can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. Said composition is generally formulated in accordance with routine procedures as a pharmaceutical composition adapted to human beings for oral administration or for intravenous administration. The amount of the active compound or a that will be effective in the treatment can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for oral, intranasal, intradermal or intravenous administration are generally about 0.01 milligram to about 75 milligrams per kilogram body weight per day, more preferably about 0.5 milligram to 5 milligrams per kilogram body weight per day.

15

It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

20

Figure Legends

Figures 1A and 1B: Netrin-1 is over-expressed in human metastatic breast tumors

Figure 1A: Expression profile of netrin-1 examined with quantitative real time reverse transcription PCR. Q-RT PCR was performed using total RNA extracted from 15 metastatic (solid bar) and 15 non-metastatic (open bar) primary tumor biopsies with specific human netrin-1 primers²⁶ and primers corresponding to the human TBP gene (TATA Binding Protein). TBP was used as a control here, as it shows a weak variability at the mRNA level between normal and breast tumoral tissues, as described in²⁵. Netrin-1 expression is given as the ratio between netrin-1 expression in each sample and the average of netrin-1 expression in the non-metastatic samples.

30

Figure 1B: Q-RT-PCR was performed using total RNA extracted from 67NR and 4T1 mouse cell lines with specific mouse netrin-1 primers and the mouse gene RPLP0 as standard.

Figures 2A-2D: Forced expression of netrin-1 in 67NR mouse cell line leads to metastasis development

Figures 2A and 2B: Mock transfected 67NR cells or 67NR cells stably transfected with netrin-1 (67NR-net) were submitted to netrin-1 expression analysis. Figure 2A, RT-PCR using specific chicken netrin-1 primers was performed using total RNA extracted from 67NR-net1 and 67NR-mock. Figure 2B, Western blot using anti-myc (chick netrin-1) or anti-netrin1 antibodies was performed.

Figure 2C: Photomicrographs of the two 67NR-net1 and 67NR-net2 clones compared to parental 67NR and to 4T1 cell line.

Figure 2D: Metastatic 4T1 cells, two control cell clones bearing puromycine resistance (67NR1 and 67NR2) and two netrin-1 expressing cell clones (67NRnet1 and 67NRnet2) were injected in fat pad of 16 mice (4 mice per cell type) and metastasis was analyzed in the lung environment. Representative photomicrographs of under-pleural and intra-parenchymatous nodules after injection of the respective cell clones (4T1, 67NR1, 67NRnet1, 67NRnet2). IPL: intra-parenchymatous lesion, UPL: under-pleural lesions.

Figures 3A-3D: Induction of mouse metastatic cell death by inhibiting the netrin-1/receptor interaction

Figure 3A: Scheme representing netrin-1 and its receptors, DCC and UNC5H.

Figures 3B, 3C, 3D: Quantitative analysis of cell death in 67NR and 4T1 cells using either DCC-EC-Fc and non specific IL3-EC-Fc as a control (figure 3B), at different concentration (figure 3C) or the more restricted DCC-5Fbn domain (figure 3D) as a competitor for netrin-1/receptor interaction. Cell death was quantified either by the trypan blue exclusion assay (figures 3B, 3D) or by caspase activity assay (figure 3C). Standard deviations are indicated (n=3).

Figures 4A and 4B: Induction of human metastatic cell death by inhibiting netrin-1/receptor interaction

Figure 4A: quantitative measurement of CAL51 cell death treated with different concentration of DCC-EC-Fc by the trypan blue exclusion assay.

Figure 4B: Quantitative analysis of cell death monitored by trypan blue exclusion in the CAL51 parental cell line or in the clonal cell line CAL51-36, treated or not with the DCC-EC-Fc competitor in culture media.

Figure 5: Netrin-1 is over-expressed in human metastatic breast tumors

5 Expression profile of netrin-1 examined with quantitative real time reverse transcription PCR. Q-RT PCR was performed using total RNA extracted from 51 tumor biopsies. They were obtained from patient with tumors localized to the breast (N0, empty bar); with only axillary node involvement (N+, gray bar) and with distant metastases at diagnosis (M+, solid bar). Specific human netrin-1 primers³⁹ and primers corresponding to
10 the human PBGD gene (TATA Binding Protein) were used. PBGD was used as a reference here, as it shows a weak variability at the mRNA level between normal and breast tumoral tissues, as described in³⁸. The other reference TBP was also used with similar results (not shown). Netrin-1 expression is given as the ratio between netrin-1 expression in each sample and the average of netrin-1 expression in the N0 samples. A non parametric
15 statistical significance test (Mann-Whitney) was used, the p value is indicated.

Figures 6A-6C: Induction of metastatic cell death by inhibiting the netrin-1/receptor interaction

Figure 6A: DCC-EC-Fc displaces DCC/netrin-1 and UNC5H2/netrin-1 interaction. ELISA assay with DCC-EC-Fc (top panel) or UNC5H2-EC-Fc (bottom panel) coated, and
20 quantification of bound netrin-1 using anti-netrin-1 antibody in the presence of increasing concentration of DCC-EC-Fc.

Figures 6B and 6C: Quantitative analysis of cell death in 67NR and 4T1 cells using either DCC-EC-Fc and non specific IL3-EC-Fc as a control. Cell death was quantified either by the trypan blue exclusion assay (figure 6B), or by caspase activity assay (figure
25 6C). Standard deviations are indicated (n=3).

Figures 7A-7C: Inhibition of metastasis formation in mice by DCC-5Fbn treatment

Figure 7A: Quantitative analysis of cell death in 67NR and 4T1 cells treated with DCC-5Fbn. MTT assay was performed on 67NR or 4T1 cells after treatment with increasing doses of DCC-5Fbn ($\mu\text{g/ml}$). Percentage of cell survival is presented. Standard
30 deviations are indicated (n=3).

Figures 7B and 7C: 4T1-luc cells were i.v. injected in BALB/c mice at day 0 and

PBS or DCC-5Fbn were injected every two days, once i.v., once i.p. starting at day 0. After 13 days, metastasis development was studied by luminescence recording (figures 7B, 7C) or by examination of lungs under a scope.

Figure 7B: A representative image of luminescence recording of PBS treated (right) or DCC-5Fbn treated (left) mice.

Figure 7C: Quantification of the luminescent signal measured by the NightOwLB system. The number of photon/pixel/sec was quantified in each animal and an index of luminescent signal is given at the ratio between the average photon/mouse in PBS treated mice to the average signal detected in DCC-5Fbn treated mice. Two independent experiments are presented (20 mice were analyzed in experiment 1, 8 mice in the experiment 2).

A representative macroscopic photograph of a lung from PBS treated mice or from DCC-5Fbn treated mice has been made (not shown) can be demonstrated in the lung from PBS treated mice.

15 **Figures 8A and 8B: Effect of DCC-5Fbn on netrin-1 expressing human cancer breast cell lines**

Figure 8A: Expression of netrin-1 examined by Q-RT PCR using total RNA extracted from 48 different breast tumor cell lines. Netrin-1 expression is given as the ratio between netrin-1 expression and the housekeeping gene HMBS expression (Hydroxymethylbilane synthase) in each sample. TBP was also used as a control here and give similar results. The two cell lines that have been selected for their high level of netrin-1 are indicated by stars.

Figure 8B: Cell death induction by DCC-5Fbn in SKBR7 and T47D cell lines. Cell death was quantified either by MTT assay as described in figure 4A (right panel) or by caspase activity measurement as described in figure 3D (left panel). Standard deviations are indicated (n=3).

Figures 9A and 9B: Human neuroblastoma

Figure 9A: Netrin-1 is a marker of aggressiveness in human neuroblastoma. Expression profile of netrin-1 examined with quantitative real time reverse transcription PCR. Q-RT PCR was performed using total RNA extracted from 101 stage 4 or 4s neuroblastoma biopsies. Tumors were either stage 4 diagnosed in patient who were less

than one year old ($4 < 1$ year) or stage 4 diagnosed in patient who were more than one year old ($4 > 1$ year). It can be noted that bad prognosis cancers (stage 4 > 1 year) show a significant over-expression of netrin-1. Student t tests were used and the p values are indicated.

5 **Figure 9B:** IMR32 cells that endogenously produce netrin-1 were treated or not with DCC-5Fbn or as a control IL3R (the interleukin-3 receptor ectodomain) and were analyzed for cell death either by measuring caspase activity (top) or by measuring cell survival via a MTT assay (down). Note that while IL3R has no effect on the death of IMR32 cells, DCC-5Fbn induces a significant IMR32 cell death. Standard deviations are
10 indicated (n=3).

Figures 10A and 10B: Glioma

Figure 10A: Netrin-1 is overexpressed in a large fraction of glioma. Expression profile of netrin-1 examined with quantitative real time reverse transcription PCR. Q-RT PCR was performed using total RNA extracted from stage II and stage III
15 oligodendroglioma and stage IV glioblastoma biopsies and was compared to normal human brain.

Figure 10B: GL26 cells that endogenously produce netrin-1 (not shown) were treated or not with DCC-5Fbn in the presence or not of an excess amount of recombinant netrin-1 and were analyzed for cell death either by measuring caspase activity (top) or by
20 measuring cell survival via a MTT assay (down). Note that DCC-5Fbn induces a significant GL26 cell death and that this effect is fully inhibited by addition of netrin-1, thus demonstrating that the DCC-5Fbn effect is directly related to inhibition of endogenous netrin-1. Standard deviations are indicated (n=3).

Figures 11A-11C: Lung cancer

25 **Figure 11A:** Netrin-1 is overexpressed in a sizeable fraction of human lung cancer. Expression profile of netrin-1 examined with quantitative real time reverse transcription PCR. Q-RT PCR was performed using total RNA extracted from lung cancer biopsies and was compared to normal tissue.

Figure 11B: H358 and H460, two NSCLC cell lines, were further used for cell
30 death assays. H358 cells that endogenously express netrin-1 and H460 cells that fail to show detectable netrin-1 expression were treated or not with DCC-5Fbn in the presence or

not of an excess amount of recombinant netrin-1 and were analyzed for cell death either by measuring caspase activity (top) or by measuring cell survival via a MTT assay (down). Note that DCC-5Fbn induces a significant H358 cell death but fails to show an effect on H460 cells. Moreover the death effect observed in H358 cells is fully inhibited by addition
 5 of netrin-1. Together with the fact that H460 cells are not sensitive to DCC-5Fbn, these data support that netrin-1 expressing lung tumor cells undergo apoptosis in response to DCC-5Fbn. Standard deviations are indicated (n=3).

Figure 11C: DCC-5Fbn inhibits xenografted H358 tumor growth in nude mice. Five-week-old (20-22 g body weight) female athymic nu/nu mice were obtained from
 10 Charles River. The mice were housed in sterilized filter-topped cages and maintained in a pathogen-free animal facility. H358 cells were implanted by s.c. injection of $5 \cdot 10^6$ cells in 200 μ L of PBS into the left flank of the mice. When tumors were established, PBS or 20 μ g of DCC-5Fbn were administered into the tumor (i.t.) everyday (duration of treatment is indicated by arrows). Tumor sizes were measured by a calliper during 41 days. The tumor
 15 volume was calculated with the formula $v = (0.5 \cdot (\text{length} \cdot \text{width}^2)) \pm \text{SE}, *$ on 6 mice treated with DCC-5Fbn and 4 mice treated with PBS. Note that while PBS treated tumors were shown to grow, DCC-5Fbn treated tumors showed a massive regression.

Figures 12A and 12B: Netrin-1 mediates DCC and UNC5H2 multimerization

Figure 12A: DCC multimerization in the presence of netrin-1 in HEK293T cells.
 20 Lysates of HEK293T cells transiently transfected with HA-DCC and/or c-myc-DCC expressing constructs together or not with netrin-1 expressing construct were subjected to myc pull-down (IP α -myc). DCC-HA presence was revealed with an anti-HA antibody.

Figure 12B: UNC5H2 dimerization in the presence of netrin-1 in HEK293T cells.
 Cell transfection and cell lysate preparation were done as in (A) but with HA-Unc5H2
 25 and/or FlagM2-UNC5H2 expressing constructs. Cell lysates were subjected to FlagM2 pull-down (IP α -Flag). HA-UNC5H2 presence was revealed with an anti-HA antibody. Total: Western blot on lysate before pull-down.

Figures 13A and 13B: Validation of the chemically-inducible system for UNC5H2 dimerization

30 **Figure 13A: Schematic representation of Fv2e-UNC5H2 fusion constructions** showing the two constructs (one tagged HA, the other one tagged c-myc) used to validate

the artificial dimerization system.

Figure 13B: Lysates of HEK293T cells transiently transfected with Fv2E-UNC5H2 tagged HA or c-myc with or without the dimerization drug (AP20187) were subjected to c-myc pull-down (IP α -myc). Total: Western blot on lysate before pull-down. HA-Fv2E-UNC5H2 presence was revealed with anti-HA antibody.

Figures 14A-14C: Forced DCC dimerization blocks its proapoptotic activity

Figure 14A: DCC-induced cell death is inhibited by dimerization induced by AP20187, as measured by trypan blue exclusion. HEK293T cells were transfected with mock plasmid (Cont.), Fv2E (Fv), Fv2E-DCC-IC (Fv-DCC) with or without AP20187 (AP). In all conditions, cells were also transfected with the surface marker pKk. Transfected cells expressing the marker were magnetically labeled with MACSelect Microbeads and separated using a MACS Separator and Separation Columns. Trypan blue exclusion was assayed on these purified cells.

Figure 14B: UNC5H2-induced cell death is inhibited by dimerization induced by AP20187, as measured by trypan blue exclusion as in (A). Cells were transfected with pMACSKk and Fv2E (Fv), Fv2E-UNC5H2-IC (Fv-UNC5H2) with or without AP20187 (AP).

Figure 14C: UNC5H2-induced caspase activation is inhibited by dimerization induced by AP20187, as measured by relative caspase-3 activity. HEK293T cells were transfected with mock vector pCMV (Cont.), Fv2E (Fv), Fv2E-UNC5H2-IC (Fv-UNC5H2) with or without AP20187 (AP). Index of relative caspase activity is presented as the ratio between the caspase activity of the sample and that measured in HEK293T cells transfected with pCMV. Standard deviations are indicated (n=3).

Figures 15A-15C: The recombinant soluble fifth fibronectin domain of DCC (DCC-5Fbn) inhibits netrin-1-induced DCC-multimerization

Figure 15A: Affinity curve of netrin-1 on DCC-5Fbn measured by ELISA test shows that DCC-5Fbn is able to bind netrin-1. DCC-5Fbn (100 ng) or IL3-R (600 ng) was coated and increasing doses of netrin-1 were added (0 to 800 ng). The IL3 values were subtracted to the DCC-5Fbn values. The approximate Kd of DCC-5Fbn/netrin-1 was estimated at 5 nM.

Figure 15B: Competition assay. As in (A) but the complete extracellular domain of

DCC (DCC-EC, 125 ng) was coated instead of DCC-5Fbn and netrin-1 was added (50 ng) in the presence of either DCC-5Fbn (625 ng) or the complete DCC-EC (125 ng). Note that DCC-5Fbn fails to compete with DCC/netrin-1 interaction.

Figure 15C: Netrin-1-induced DCC multimerization is inhibited by DCC-5Fbn.

5 Lysates of HEK293T cells transiently transfected with HA-DCC and/or c-myc-DCC expressing constructs with or without netrin-1 (300 ng/mL) and/or DCC-5Fbn (900 ng/mL) were subjected to HA pull-down (IP α -HA). c-myc-DCC presence was revealed with anti-c-myc antibody. Total: Western blot on lysate before pull-down.

Figures 16A and 16B: DCC-5Fbn antagonizes netrin-1-blocking effects on DCC-
10 **induced cell death**

Figure 16A: HEK293T cells were transiently transfected with a mock (Cont.) or a full length DCC construct and incubated or not with netrin-1 (300 ng/ml) and/or DCC-5Fbn (800 ng/mL). Cell death was assessed by trypan blue staining.

Figure 16B: Metastatic breast cancer cells 4T1 were cultured in the presence (+
15 DCC-5Fbn) or absence (- DCC-5Fbn) of DCC-5Fbn (300 ng/mL) for 24 hours and cell death was also measured by trypan blue exclusion assay. Standard deviations are indicated (n=3).

Example 1: Materials and Methods

20 **Cell line, cell cultures, transfection procedure, reagents and immunoblots:**

4T1 and 67NR cells were a kind gift from F. Miller (Detroit, MI, USA). Cal51, MCF7, MDA-MB231, 453, 361, 157, SK-BR3, CAMA-1, T47D were cultured using standard procedure. Human breast cell lines listed in figure 8B and more specifically T47D and SKB7 cell lines were obtained from D. Birnbaum. 67NR cells were stably transfected using
25 the lipofectamine reagent (Invitrogen) and puromycin (Sigma) selection. Transient transfections of Human Embryonic Kidney 293T cells (HEK293T) were performed as previously described¹⁰ according to a modified calcium phosphate procedure or using Lipofectamine according to the manufacturer's instructions (Invitrogen). The breast cancer 4T1 cell line was described previously²⁰. 4T1-luc cells were obtained by stable transfection
30 of a CMV-luciferase vector bearing hygromycin resistance. Clones were selected by luminescence intensity using the luminoskan Ascent Station (Labsystems). Immunoblots

were performed as described previously ⁶ using anti-c-myc (Sigma; 1/200) anti-FlagM2 (Sigma, 1/200) or anti-HA (Sigma; 1/500). The artificial dimerizing agent AP20187 was from Ariad Pharmaceuticals. The complete extracellular domain of DCC (DCC-EC), DCC-EC-Fc were obtained from R&D system and Netrin-1 from Apotech corp. For cell death
 5 analysis, caspase activity measurement and immunoprecipitation, AP20187 was used at a final concentration of 10 nM and netrin-1 was used at a final concentration of 300 ng/mL.

Human breast tumors samples:

51 human breast cancer samples were provided by the tumor bank of the Centre Léon
 10 Bérard. Fresh tissue of the tumor was obtained during breast surgery prior any systemic therapy and snap-frozen in liquid nitrogen.

Site directed mutagenesis and plasmid constructs:

PGNET-1 pCMV and pGNET-1 encoding chick netrin-1 were was previously described ⁶.
 15 pKk was described ²². The dominant negative mutants for DCC (pCR-DCC-IC-D1290N) and for UNC5H (pCR-UNC5H2-IC-D412N) have been previously described ^{6,27,7}.

HA-DCC was obtained by introducing a HA tag in the template pCMV-DCC ⁶ by QuikChange site-directed mutagenesis system (Stratagene) using the following primers:
 DCC-HA F: 5'-CACAGGCTCAGCCTTTTATCCATATGATGTACCGGATTATGCATA
 20 ACATGTATTCTGAATG-3' (SEQ ID NO:1); DCC-HA R: 5'- CATTGAGAAA
 TACATGTTATGCATAATCCGGTACATCATATGGATAAAAGGCTGAGCCTGTG-3'
 (SEQ ID NO:2).

c-myc-DCC was also obtained by introducing a c-myc tag in the template pCMV-DCC by QuikChange using the following primers: DCC-myc F: 5'-
 25 CACAGGCTCAGCCTTTGAGCAGAAGTTGATAAGTGAGGAAGATCTGTAACATG
 TATTCTGAATG-3' (SEQ ID NO:3). DCC-myc R: 5'- CATTGAGAAATACATGTTAC
 AGATCTTCCTCACTTCTCAACTTCTGCTCAAAGGCTGAGCCTGTG-3' (SEQ ID
 NO:4).

HA-Fv2E encoding expression vector (in pC4M) from the Argent Regulated
 30 Homodimerization kit is from Ariad Pharmaceuticals. From this plasmid, the HA-Fv2E-DCC-IC plasmid was constructed. A PCR fragment of the intracellular domain of DCC

(1122-1447) was obtained with the primers: F 5'-TATGTCGACCGACGCTCTTCAGCCCAGCAGAGA-3' (SEQ ID NO:5) and R 5'-TATGAATTCTTAGTCGAGTGCGTAGTCTGGTACGTCGTACGGATAAAAGGCTGAGCCTGTGATGGCATTAAAG-3' (SEQ ID NO:6).

- 5 The reverse primer fused to the HA tag to C-terminal end of DCC. The PCR fragment was subcloned in HA-Fv2E by SalI and EcoRI restriction digestion. The c-myc-Fv2E-DCC-IC was obtained using the QuikChange site-directed mutagenesis system (Stratagen) with pC4M-Fv2E-DCC-IC-HA as template and the following primers: primer F: 5'-CTTAATGCCATCACAGGCTCAGCCTTTGAACAGAACTCATCTCTGAAGAGGAT
- 10 CTGTAAGAATTCATAAAGGGCAAT-3' (SEQ ID NO:7) and primer R: 5'-ATTGCCCTTTATGAATTCTTACAGATCCTCTTCAGAGATGAGTTTCTGTTCAAAGGCTGAGCCTGTGATGGCATTAAAG-3' (SEQ ID NO:8).

- HA-UNC5H2 (in pcDNA3.1) has already been described⁷ the constructs encoding FlagM2-UNC5H2 was generated by cloning in p3xFlag-CMVTM-7.1 (Sigma) the NotI-EcoRI PCR
- 15 fragment derived from HA-UNC5H2 as template and the following primers: primer F 5'-GCGCGGCCCGCAGGGCCCGGAGCGGG-3' (SEQ ID NO:9) and primer R 5'-CGGAATTCTCAGCAATCGCCATCAGTGGTC-3' (SEQ ID NO:10).

- HA-Fv2E-UNC5H2-IC- and c-myc-Fv2E-UNC5H2-IC in pC4M were generated by PCR amplification of the UNC5H2 intracellular domain using the following primers: UNC5H2-
- 20 HA F 5'-CGGTCGACGTGTACCGGAGAACTGC-3' (SEQ ID NO:11) and UNC5H2-HA R 5'-GCGAATTCTCATGCATAATCCGGCACATCATACGGATAGCAATCGCCATCAGTGGTC-3' (SEQ ID NO:12), and UNC5H2-myc F 5'-CGGTCGACGTGTACCGGAGAACTGC-3' (SEQ ID NO:13) and UNC5H2-myc R 5'-GCGAATTCTCACAGATCCTCTTCTGAGATGAGTTTTTGTTCGCAATCGCCATCA
- 25 GTGGTC-3' (SEQ ID NO:14) respectively. The PCR fragments were cloned in HA-Fv2E by SalI and EcoRI restriction digestion.

- The cDNA encoding the HA-Fv2E-UNC5H2-IC and c-myc-Fv2E-UNC5H2-IC fusion proteins were then subcloned in pcDNA3.1-TOPO by PCR using the following primers: Fv2E F 5'-CCACCATGGGGAGTAGCA-3' (SEQ ID NO:15) and UNC5H2-HA
- 30 R 5'-TCATGCATAATCCGGCACATCATACGGATAGCAATCGCCATCAGTGGTC-3' (SEQ ID NO:16), and Fv2E F 5'-CCACCATGGGGAGTAGCA-3' (SEQ ID NO:15) and

UNC5H2-myc R 5'-TCACAGATCCTCTTCTGAGATGAGTTTTTGTTCGCAATC
GCCATCAGTGGTC-3' (SEQ ID NO:17) respectively and HA-Fv2E-UNC5H2-IC and c-
myc-Fv2E-UNC5H2-IC in pC4M as respective templates.

- Ps974-DCC-5Fbn allowing bacterial expression of the fifth fibronectin type III domain of
5 DCC was obtained by inserting a PstI/BamHI DNA fragment generated by PCR using
pDCC-CMV-S as a template.

DCC-5Fbn production:

- DCC-5Fbn production was performed using a standard procedure. Briefly, BL21 cells were
10 forced to express DCC-5Fbn in response to imidazole and the BL21 lysate was subjected to
affinity chromatography using Flag-agarose (Sigma).

Immunoprecipitation:

- Coimmunoprecipitations were carried out on HEK293T cells transfected with various
15 tagged constructs as described previously ²⁷ Briefly, HEK293T cells were lysed in 50 mM
HEPES pH 7.6, 125 mM NaCl, 5 mM EDTA and 0.1% NP-40 in the presence of protease
inhibitor, and further incubated with anti-HA (Sigma), anti-c-myc antibody (Sigma), anti-
FlagM2 (Sigma) and protein-A Sepharose (Sigma). Washes were done in 50 mM HEPES
pH 7.6, 125 mM NaCl, 5 mM EDTA.

20

Binding assay and ELISA competition assay:

- DCC-5Fbn (100ng) or IL3-R (R&D systems, 600ng) was coated on maxisorp plate (Nunc)
and increasing doses of netrin-1 (Apotech) were added (0 to 800ng) for binding assay.
DCC-EC (R&D systems, 125ng) was coated on maxisorp plate for ELISA competition
25 assay. Netrin-1-FlagM2 (50ng) and competitor DCC-EC (125ng) or DCC-5Fbn (625ng)
were then added simultaneously. After washes, for both binding assay or ELISA
competition assay, residual netrin-1-FlagM2 still fixed was revealed with an anti-FlagM2
antibody (Sigma).

- 30 **DCC/netrin-1 ELISA assays:**

DCC-EC-Fc (1.25ng/ml) or UNC5H2-EC-Fc (0.5ng/ml) was adsorbed on 96-well maxisorp

plate (Nunc) according to manufacturer instruction. Flag-tagged Netrin-1 (0.5ng/ml) was then added together with increased concentrations of DCC-EC-Fc. After a 1 hour incubation, plates were extensively washed and bound netrin-1 was detected by immunolabelling using an anti-flagM2 antibody (Sigma) and a HRP-goat-anti-mouse (Jackson). Colorimetric measurement was performed on the multilabel Victor station (Wallac).

Cell death assays:

67NR, 4T1, CAL51, T47D and SKBR7 were grown in serum-poor medium and were treated (or not) with DCC-EC-Fc or DCC-5Fbn for 24hours. Cell death was analysed using trypan blue staining procedures as described previously ⁶. The extent of cell death is presented as the percentage of trypan blue-positive cells in the different cell populations. To select transfected cells, cells were co-transfected with the surface marker pKk and the plasmid encoding genes of interest. Transfected cells expressing the marker were magnetically labeled with MACSelect Microbeads and separated using a MACS Separator and Separation Columns (Miltenyi Biotec). Trypan blue exclusion was assayed on these purified cells. Cell survival was also measured by MTT assay using Vybrant MTT assay kit (Molecular Probes) according to the manufacturer procedures.

Caspase activity measurement:

Relative Caspase activity was determined by flow cytometric analysis as follows: 2.10^5 treated cells were harvested, washed once in 1 ml PBS, and resuspended in 200 μ l staining solution containing FITC-VAD-fmk (CaspACE, Promega). After incubation for 60 min at 37°C, cells were washed in 1 ml PBS and resuspended in 200 μ l PBS for flow cytometry analysis. Stained cells were counted using a FACS Calibur (Becton Dickinson) and CellQuest analysis software with excitation and emission settings of 488 nm and 525-550 nm (filter FL1), respectively. Caspase-3 activity was measured by using the Caspase-3 assay from BioVision. Caspase activity is presented as the ratio between the caspase activity of the sample and that measured in HEK293T cells transfected with pCMV. For cell death analysis and caspase activity measurement, AP20187 or/and netrin-1 or/and DCC-5Fbn were added in cell culture medium 20 hours and 1 hour before collecting cells.

Quantitative RT-PCR:

To assay netrin-1 expression in human breast tumors, total RNA was extracted from biopsies of patients undergoing surgery for breast cancer using Nucleospin RNAII kit (Macherey-Nagel) and 1 µg was reverse-transcribed using the iScript cDNA Synthesis kit (BioRad). Real-time quantitative RT-PCR was performed on a LightCycler 2.0 apparatus (Roche) using the Light Cycler FastStart DNA Master SYBERGreen I kit (Roche). Reaction conditions for all optimal amplification, as well as primer selection of netrin-1, were determined as already described¹⁸. The ubiquitously expressed human PBGD, TBP and mouse RPLP0 genes showing the less variability in expression between normal and breast tumoral tissues^{25 28} were used as internal controls. The following primers were used:

PBGD:

- FOR: 5'-CTGGAGTTCAGGAGTATTCGGGG-3' (SEQ ID NO:18),
- REV: 5'-CAGATCCAAGATGTCCTGGTCCTT-3' (SEQ ID NO:19);

TBP:

- FOR: 5'-CACGAACCACGGCACTGATT-3' (SEQ ID NO:20),
- REV: 5' TTTTCTTGCTGCCAGTCTGGAC 3' (SEQ ID NO:21);

Human netrin-1-NTN1:

- FOR: 5'-TGCAAGAAGGACTATGCCGTC-3' (SEQ ID NO:22),
- REV: 5'-GCTCGTGCCCTGCTTATACAC-3' (SEQ ID NO:23);

UNC5B:

- FOR: 5'-TGCAGGAGAACCTCATGGTC-3' (SEQ ID NO:24),
- REV: 5'-GGGCTGGAGGATTACTGGTG-3' (SEQ ID NO:25);

DCC:

- FOR: 5'-AGCCAATGGGAAAATTACTGCTTAC-3' (SEQ ID NO:26),
- REV: 5'-AGGTTGAGATCCATGATTTGATGAG-3' (SEQ ID NO:27);

UNC5C:

- FOR: 5'-GCAAATTGCTGGCTAAATATCAGGAA-3' (SEQ ID NO:28),
- REV: 5-GCTCCACTGTGTTCAGGCTAAATCTT-3' (SEQ ID NO:29).

30 Mice, intraveinuous and mammary gland injections, measurement of metastasis development:

Syngenic mice model. Female BALB/cByJ mice of 8-11 weeks of age from Jackson Laboratory were used for surgery. For mammary gland injection of 67NR cells, mice were anesthetized with 2,2,2-tribromoethanol and 10^6 cells in 50 μ l PBS were injected into the mammary gland and mice were sacrificed when the tumor exceeded 1.5 cm and caused
 5 impediment to the movement of the animal. For intravenous injection, 10^5 tumor 4T1-luc cells in 150 μ l PBS were injected into a tail vein and mice were either sacrificed at day 13-15 (after 4T1 cells injection) or at day 20-23 (after 67NR cells injection) or analyzed using luminescence recording. When animals were sacrificed, lungs were removed, weighed and compared to the whole weight of the animal, and metastatic nodules counted.

10

Xenograft in nude mice:

Five-week-old (20-22 g body weight) female athymic nu/nu mice were obtained from Charles River. The mice were housed in sterilized filter-topped cages and maintained in a pathogen-free animal facility. Human breast cancer cell lines (SKBR7, T47D and H358)
 15 were implanted by s.c. injection of $5 \cdot 10^6$ cells in 200 μ L of PBS into the left flank of the mice. When tumors were established (5 weeks for T47D, 2 weeks for SKBR7 and 5 days for H358), PBS or 20 μ g of DCC-5Fbn were administered into the tumor (i.t.) everyday during 14 days. Tumor sizes were measured by a caliper. The tumor volume was calculated with the formula $v = 0.5 \cdot (\text{length} \cdot \text{width}^2)$.

20

Tumor analysis:

4 μ m-thick lung sections were prepared and stained with hematoxylin-eosin-saffron. Histological classification and grading of neoplastic lesions was performed in a blinded fashion and according to standard procedures. For in vivo imaging of metastasis using 4T1-
 25 luc cells, the light resulting from the bioluminescent oxidation of the intra-peritoneally injected endotoxin-free luciferin (Promega) (120 mg/kg bodyweight) was detected and quantified (10 minutes after injection) with a NightOWL LB 981 NC 100 system from Berthold Technologies, using an anaesthesia system with gaseous isoflurane from TEM SEGA.

30

Example 2: Netrin-1 dictates metastasis of breast tumor by inhibiting apoptosis

We first analysed netrin-1 and its dependence receptors -i.e., DCC and UNC5H expression by Q-RT-PCR in a panel of 30 breast primary tumors, 15 of which were without known metastatic evolution, and 15 that were metastatic at diagnosis. While DCC was barely detectable and UNC5H failed to show significant change between the two types of tumors, netrin-1 appeared to be significantly more expressed in metastatic breast tumors than in non-metastatic breast tumors (figure 1A).

60% of tested metastatic breast tumors showed an over-expression of netrin-1 (range from 1.4 to 9.6 fold, $p < 0.015$) (Table 1).

- 10 Table 1: The percentage of samples showing a netrin-1 expression higher than the average expression in non-metastatic biopsies is indicated, as is the range of the over-expression.

n = 15	metastasis	non metastasis
% of breast tumors that over-express netrin-1	60	33
Range of over-expression of netrin-1	1.4-9.6	1.6-2.9

- In mice, Miller and colleagues developed a powerful model to study the biology of metastatic versus non-metastatic tumors: from a single primary mammary tumor that occurred naturally in a BALB/c mouse, a series of cell lines were obtained that showed different metastatic potentials when injected into syngenic mice. In particular, while 67NR cells form primary mammary tumors but no metastasis, 4T1 cells form primary tumors and metastasis, especially in the lung, the bone marrow and the liver ²⁰. Interestingly, while netrin-1 failed to be detected in 67NR cells, netrin-1 was highly expressed in 4T1 cells (figure 1B).

- To assay whether the metastatic potential of 4T1 cells, compared to that of 67NR cells, was related to netrin-1 expression, 67NR cells were forced to stably express netrin-1. Mock transfected 67NR cells or 67NR-net cells that express netrin-1 (figures 2A, 2B) were injected in mammary gland or i.v. and metastasis was monitored by anatomo-pathology examination of lungs. Both cell lines failed to form metastasis when injected in fat pad, suggesting that the presence of netrin-1 in 67NR is not sufficient to allow lung metastasis formation from the primary site. However, when cells were injected i.v., a significant

increase of metastasis in the lungs was detected in the netrin-1 expressing 67NR (figure 2C).

See Table 2 showing the number of under-pleural (metastasis outside the lung) and intra-parenchymatous nodules (metastasis in the lung).

5 Table 2:

mice injected with clone:	under-pleural lesions		Intra parenchymatous Lesions (lung metastasis)	
	Number of lung Affected	Number of noduled per lung (range)	Number of lung affected	Number of nodules per lung (range)
67NR1	3	0-5	0	0
67NR2	2	0-2	0	0
67NR-net1	3	0-5	1	0-4
67NR-net2	1	0-3	2	1-2

Thus, netrin-1 expression appears to be a crucial event that supports metastasis formation, probably by favoring tumor cells after intravation.

Because netrin-1 appears to be sufficient for the metastatic potential of 67NR cells after intravation and because netrin-1 was shown to inhibit netrin-1 dependence receptors-induced cell death ^{6, 7, 18}, we next investigated whether autocrine production of netrin-1 provides a selective advantage to 4T1 cells by inhibiting DCC/UNC5H-induced cell death in these cells. A domain located in the N-terminus of netrin-1 (the so-called laminin-VI domain) interacts with both DCC and UNC5H receptors (figure 3A; ²¹), so that a soluble extracellular domain of DCC (DCC-EC-Fc) can inhibit both DCC/netrin-1 and UNC5H/netrin-1 interaction (not shown). DCC-EC-Fc was then added to a culture of 4T1 cells and cell death was monitored either by a trypan blue exclusion assay (figure 3B) or by measuring caspase activity (figure 3C). As shown in figure 3C, addition of the competing protein in the culture medium triggers death of 4T1 cells in a dose-dependent manner. Moreover, this effect is specific, as DCC-EC-Fc had no effect on 67NR cell death and IL3R-EC-Fc (the extracellular domain of IL3 receptor) failed to trigger 4T1 cell death (figures 3B, 3C). This effect is due to netrin-1 inhibition, as addition of an excess amount of netrin-1, together with DCC-EC-Fc inhibited the pro-apoptotic activity of DCC-EC-Fc on

4T1 cells (not shown). To restrict the competition to a smaller domain, we produced the fifth fibronectin type III domain of DCC, which is known to interact with netrin-1²¹. Addition of this domain -DCC-5Fbn- had a similar pro-apoptotic activity on 4T1 cells (figure 3D). Thus, while netrin-1 appears to confer metastatic potential to tumor cells in mice, these netrin-1 expressing metastatic tumor cells can be engaged toward apoptosis by inhibition of the netrin-1/receptors interaction.

To further analyse whether this holds true in human breast tumor cells, netrin-1 expression was analysed in a panel of human metastatic breast cancer cell lines (see Table 3).

Table 3:

Human breast carcinoma cell line	Netrin-1 transcriptional expression	DCC-EC-Fc sensitivity
MDA-MB 157	++++	+/-
MCF-7	++++	-
CAMA-1	+++	-
SKBR3	++	ND
SAV-NUDE	++	ND
Cal51	++	+++
MDA-MB231	+	++
MDA-MB453	+	+
T47D	-	ND
T47D*	++	++

* Carried out on another T47D cell line

Table 3 showing the different human metastatic breast cell lines analysed for the netrin-1 expression by Q-RT PCR as in figures 1A, 1B, and their sensitivity to DCC-EC-Fc by measurement of cell death by trypan blue exclusion. The relative amount of netrin-1 expression and DCC-EC-Fc sensitivity are indicated by (+), while the absence of these

criteria is indicated by (-). In some cell lines the DCC-EC-Fc has not been determined (ND).

As expected, netrin-1 is expressed in a large number of metastatic cell lines and some of them undergo apoptosis when cultured in the presence of DCC-EC-Fc. As an
 5 example, CAL51 cells underwent apoptosis in a dose-dependent manner in response to DCC-EC-Fc. As above, addition of netrin-1 in excess reverts the effect of DCC-EC-Fc, supporting the view that the competing proteins kill these human cell lines by inhibiting the netrin-1/netrin-1 receptors interaction. Moreover, a clonal selection from CAL51 cells allowed the establishment of a CAL51-36 cell line, that is much more susceptible to cell
 10 death in response to DCC-EC-Fc (figure 4B). Because the DCC-EC-Fc or DCC-5Fbn may consequently represent good tools to trigger selective apoptosis of human metastatic tumors cells.

Here we show that netrin-1 expression may be considered as a marker of breast tumor dissemination. More than half of the breast tumors with metastasis propensity
 15 showed elevated netrin-1 expression. Both the mice model described above and the data obtained on human breast cancer cell lines support the view that this elevated netrin-1 level is a selective advantage acquired by the cancer cell to escape netrin-1-dependence receptors induced apoptosis and, consequently, to survive independently of netrin-1 availability. From a mechanistic point of view, this autocrine expression of netrin-1 inhibits cell death
 20 induced by UNC5H. Indeed, DCC was barely detectable in the two groups -metastatic and non metastatic- of breast cancers studied, hence suggesting that DCC is either down-regulated early during breast tumorigenesis or is only weakly expressed in breast tissue. Moreover, inhibition of UNC5H-induced apoptosis by co-expression of a dominant negative mutant form of the UNC5H pro-apoptotic activity inhibits CAL51 cell death in
 25 response to DCC-EC-Fc (not shown). This may fit with the recent observation that part of UNC5H2 pro-apoptotic activity passes through the activation of the serine/threonine DAPK²² a protein involved in metastasis regulation²³.

These observations not only provide evidence for the importance of the ligand/dependence receptor pair in the regulation of tumor development, but also enlighten
 30 a new therapeutic strategy. Indeed, as of today, there is no efficient treatment for patients with metastatic breast cancer, a lack of treatment that leads to the death of 400,000 women

worldwide per year ²⁴. Here we propose that a treatment based on inhibition of the interaction between netrin-1 and its dependence receptors could positively affect half of the patients suffering from metastatic breast cancer. These treatments could include chemical drugs, monoclonal antibodies or the DCC-5Fbn protein presented here. Whether this should be considered as a strategy preventing metastasis formation, which would imply a long-term preventive treatment on women diagnosed with primary breast cancer, or as a strategy that could be used to induce metastasis regression remains to be shown. Future clinical trials should also answer this point.

Here we describe that, unlike human non-metastatic breast tumors, the majority of metastatic breast cancers shows an over-expression of netrin-1. In a mice model, we demonstrate that in non-metastatic mammary tumor cells, forced expression of netrin-1 is associated with metastasis in the lungs. Moreover, mice or human metastatic tumor cell lines, that were shown to highly express netrin-1, undergo apoptosis when the netrin-1/receptors interaction is inhibited by a competing protein. Thus, netrin-1 is a marker for human metastatic cancer such as metastatic breast and inhibition of the netrin-1/receptors interaction represents a therapeutic approach to induce metastatic cell death.

Example 3: Restoration of the netrin-1 dependence receptors pathway triggers apoptosis in metastatic breast tumors

Netrin-1 and its dependence receptors -i.e., DCC, UNC5H2, UNC5H3 expression were analysed by Q-RT-PCR in a panel of 51 breast tumors. It includes patients whose tumors were either localized to the breast (N0, 16 patients), had nodal involvement (N+, 19 patients) or had distant metastatic disease at the time of diagnosis (M+, 16 patients). While DCC was barely detectable and UNC5H expression failed to display significant changes between the different types of tumors (not shown), netrin-1 is significantly more expressed in N+ tumors than in N0 tumors (median: 1.8 versus 0.5, $p=0.007$) with a range of netrin-1 expression higher in N+ tumors (figure 5 and Table 4).

Table 4: The percentage of samples showing a netrin-1 expression higher than the average expression in N0 biopsies, 5 fold higher or 15 fold higher is indicated, as is the range of the over-expression.

n = 51		N0 Localised to breast (n=16)	N+ Nodal involvement (n=19)	M+ Distant metastasis (n=16)
% of breast tumors that over-express netrin-1		31	73.7	93.7
% of breast tumors that over-express netrin-1	More than 5 fold	0	31.5	62.5
	More than 15 fold	0	0	37.5
Range of over-expression of Netrin-1		0.02-4.6	0.03-12.8	0.6-111.7

5

31.5% of the N+ tumors show at least a 5 fold increase in netrin-1 expression while no such increase was detected in any tested N0 tumors (figure 5 and Table 4). An even more striking difference is observed when comparing netrin-1 expression in M+ versus N0 tumors (median: 7.8 versus 0.5, $p < 0.0001$). Along this line 62.5% of M+ tumors show at least a 5 fold increase in netrin-1 expression. A significant difference in netrin-1 expression also exists between N+ and M+ tumors (median: 1.8 versus 7.8, $p = 0.009$). Moreover, netrin-1 overexpression is higher in M+ tumors than in N+ tumors, as 37.5% of M+ tumors display more than a 15 fold increase in netrin-1 level, while such an increase is not detected in N+ tumors (figure 5 and Table 4). Thus, netrin-1 up-regulation is a marker of nodal involvement and distant metastatic disease in human breast cancer.

In mice, Miller and colleagues developed a powerful model to study the biology of metastatic versus non-metastatic tumors: from a single primary mammary tumor that occurred naturally in a BALB/c mouse, a series of cell lines were obtained that showed different metastatic potentials when injected into syngenic mice. In particular, while 67NR cells form primary mammary tumors but no metastasis, 4T1 cells form primary tumors and metastasis, especially in the lung, the liver and the bone marrow²⁰. Interestingly, while netrin-1 failed to be detected in 67NR cells, netrin-1 was highly expressed in 4T1 cells (figure 1B).

To first assay whether the metastatic potential of 4T1 cells, compared to that of 67NR cells, was related to netrin-1 expression, 67NR cells were forced to stably express

25

netrin-1. Mock transfected 67NR cells or 67NR cells that express netrin-1 (figures 2A and 2B) were injected into mammary glands and metastasis was monitored by anatomico-pathological examination. Both cell lines failed to efficiently form metastasis in liver or in lungs when injected in mice fat pads (19 mice were injected with netrin-1 expressing 67NR cells and only two suspicions of micro-metastases, one in the lung and one in the liver were detected) (Table 5).

Table 5: Lungs and liver metastasis of fat pad-injected 67NR versus netrin-1 expressing cells. One control cell clone bearing puromycine resistance (67NR-mock), one netrin-1 expressing cell clone (67NRnet1) and one polyclonal population of netrin-1 stably transfected 67NR (67NR-net1-polyclonal) were injected in fat pad of mice and metastasis was analyzed in the lung or liver environment.

Cells injected	Mice (n)	Primary tumors	Metastasis	Comment
67NR-mock	9	9	0	
67NR-net1	7	7	0	Suspicion of 1 micrometastase in liver
67NR-net1 polyclonal	12	12	0	Suspicion of 1 micrometastase in lung

Thus, netrin-1 expression in tumor cells is not sufficient to enable metastasis formation from the primary site.

Because netrin-1 was shown to inhibit netrin-1 dependence receptors-induced cell death^{6, 7, 18}, we next investigated whether the autocrine production of netrin-1 detected in metastatic 4T1 cells confers a selective advantage to these cells, by inhibiting DCC/UNC5H-induced cell death. To assay this, we looked for a compound that may titrate netrin-1. It was reported that a domain located in the N-terminus of netrin-1 (the so-called laminin-VI domain) interacts with both DCC and UNC5H receptors (figure 3A;²¹). We show that a soluble extracellular domain of DCC (DCC-EC-Fc) can inhibit both DCC/netrin-1 and UNC5H2/netrin-1 interaction, as measured by ELISA assay (figure 6A). DCC-EC-Fc was then added to a culture of 4T1 cells and cell death was monitored, either by a trypan blue exclusion assay (figures 3B and 6B) or by measuring caspase activity by flow cytometry (figures 3C and 6C). As shown in figures 3B, 3C, 6B and 6C addition of the

competing protein in the culture medium triggers death of 4T1 cells in a dose-dependent manner. This effect is specific, as DCC-EC-Fc had no effect on 67NR cell death (figures 3B, 3C, 6B and 6C) and IL3R-EC-Fc (the extracellular domain of the IL3 receptor) failed to trigger 4T1 cell death (figure 3D). Thus, 4T1 cells survive through autocrine production of
 5 netrin-1, which blocks netrin-1 receptors-induced cell death.

Because the complete extracellular domain of DCC appears as only of modest interest for use in vivo and in therapy (DCC-EC-Fc is about 1100 amino-acid large), we looked for an alternative polypeptide from the DCC extracellular domain, which could trigger apoptosis in 4T1 cells. We consequently produced the fifth fibronectin type III
 10 domain of DCC, DCC-5Fbn, which is known to interact with netrin-1 ²¹ (figure 3A). Interestingly, this 100 amino-acid protein does not interfere with the binding of DCC/netrin-1 or UNC5H/netrin-1, but affects the ability of netrin-1 to trigger multimerization of these receptors (see Example 4). As DCC and UNC5H multimerization is a pre-requisite for the netrin-1 inhibitory activity on DCC/UNC5H-induced cell death, the
 15 addition of DCC-5Fbn triggers apoptosis in DCC-expressing cells cultured in the presence of netrin-1 ²² and triggers death of both 4T1 (figure 7A).

We next investigated whether the cell death effect observed in vitro may be extended in vivo. To do so, 4T1 cells were stably transfected with a luciferase-based vector and 4T1-luc cells were intraveinously (i.v.) injected into syngenic BALB/c mice. Mice were
 20 then intraperitoneally (i.p.) and i.v injected (1 injection every two days, once i.v., once i.p.) from day 0 to day 13 with either PBS buffer or Flag-tagged-DCC-5Fbn (1.25 µg/mouse g/injection). Metastasis formation was then analyzed using luminescence recording. As shown in figures 7B and 7C, when i.v. injected, 4T1-luc cells efficiently colonize lungs. On the opposite, mice treated with DCC-5Fbn show a dramatic reduction of lung metastasis
 25 (figures 7B and 7C). This inhibition of metastasis formation was then confirmed by anatomo-pathological examination of lungs, (not shown, see Table 6).

Table 6: Total number of lung metastatic nodules in individual mice were counted under a dissection scope in the two-treated populations (+PBS, +DCC-5Fbn)

Treatment	Mice (n)	Average of Metastasis per mouse	Range of metastasis per mouse
PBS	10	42.4	0-75
DCC-5Fbn	10	2.6	0-6

5 Similar results were obtained when we performed daily i.p. injection of GST-tagged-DCC-5Fbn instead of Flag-tagged-DCC-5Fbn and GST-FADD instead of PBS (not shown). Thus, in mice, the inhibition by DCC-5Fbn of the pro-survival activity conferred by netrin-1 autocrine expression is associated with metastasis prevention.

10 The acquired survival advantage through netrin-1 autocrine expression is not restricted to murine tumor cells, as it is detected in human breast cancer cell lines. Indeed, netrin-1 was shown to be expressed in a sizeable fraction of human breast cancer lines (figure 8A) and addition of DCC-EC-Fc or DCC-5Fbn to naturally netrin-1 expressing human breast adenocarcinoma T47D or SKBR7 cell cultures triggers cell death induction measured either by caspase-3 activity assay or MTT assay (figure 8B and not shown). This
15 effect is due to netrin-1 inhibition, as addition of an excess amount of netrin-1, inhibited the pro-apoptotic activity of DCC-EC-Fc/DCC-5Fbn (not shown). To monitor the anti-tumor effect of DCC-5Fbn, xenografts of T47D cells were implanted in nude mice. When tumors reached a palpable size, mice were daily treated with either PBS or DCC-5Fbn and tumor volume was determined for 18 days. Similarly to the data obtained in the syngenic model
20 above, DCC-5Fbn fully inhibits tumor growth (Table 7).

Table 7: showing the number and behavior of xenografted T47D tumors that have been treated either with PBS or DCC-5Fbn. The number of tumors that has grown in size more than 40% and the number of tumors that has a reduced size (more than 30%) are indicated

Treatment	Number of mice	Tumor growth (> 40 %)	Tumor regression (> 30 %)
PBS	4	3	0
DCC-5Fbn	5	0	3

Here we show that netrin-1 expression may be considered as a marker of breast tumor ability to disseminate. Most of the breast tumors with metastasis propensity showed elevated netrin-1 expression. Both the data obtained on human/mice breast cancer cell lines and the syngenic/human xenograft mice models described above and support the view that this elevated netrin-1 level is a selective advantage acquired by the cancer cell to escape netrin-1-dependence receptors induced apoptosis and, consequently, to survive independently of netrin-1 availability. From a mechanistic point of view, in the human pathology, this autocrine expression of netrin-1 probably inhibits UNC5H-induced cell death. Indeed, DCC was barely detectable in the different groups (N0, N+, M+) of breast cancers studied, hence suggesting that DCC is either down-regulated early during breast tumorigenesis or is only weakly expressed in breast tissue. Moreover, inhibition of UNC5H-induced apoptosis by co-expression of a dominant negative mutant form of the UNC5H pro-apoptotic activity inhibits human breast cancer cell death in response to DCC-EC-Fc (not shown).

Thus, as predicted by the dependence receptor model, we have now shown that a tumor cell can escape dependence receptor dependency in at least three manners. First, expression of the dependence receptor can be down-regulated, as extensively described for DCC and more recently for UNC5H^{15, 17, 19, 29}. Second, the downstream death signalling can be shut down. Along this line, we have recently shown that UNC5H2 pro-apoptotic activity relies on the binding of UNC5H2 to the serine/threonine DAPK²², a protein that was demonstrated to be involved in metastasis regulation and down-regulated in human malignancy²³. Similarly, a recent report by Stupack and colleagues shows that, in the case of some integrins that act as dependence receptors, caspase-8, which triggers the cell death mediated by these integrins, is crucial for neuroblastoma metastasis³⁰. Here we show that a third selective advantage for the tumor cell is the self-production of the dependency ligand. One intriguing question remains as to why breast tumors with metastatic propensity seem to have preferably selected netrin-1 self-production rather than receptor loss, while colorectal tumors have mostly selected loss of the receptors rather than gain of netrin-1 expression - indeed, only 7% of colorectal cancers show an increase of netrin-1 expression¹⁸. A possible explanation is that netrin-1 expression not only confers a gain in survival to the migrating cells, but also possibly a gain in the non-apoptotic/positive signalling of netrin-1 receptors.

Along this line, it is important to note that netrin-1 was originally described as a guidance cue ³¹, which, even though completely unproven, could play a role in the tropism of metastatic cells. Other proposed roles of netrin-1 include adhesion and morphogenesis regulation ³²⁻³⁴, both mechanisms that may be of importance for metastasis development.

5 Similarly, netrin-1 was recently proposed to play a role during embryonic angiogenesis and even though conflicting results have been published ³⁶⁻³⁸, we cannot at this stage discard the role of netrin-1 as an angiogenic factor that somehow could favor metastasis development at the secondary site. However, the gain of “positive” signalling by netrin-1 autocrine expression is probably not sufficient per se to promote metastasis, as forced expression of
10 netrin-1 in non-metastatic cells failed to be associated with metastasis formation.

These observations not only provide evidence for the importance of ligand/dependence receptors pairs in the regulation of tumor development, but also enlighten a new therapeutic strategy. Indeed, as of today, there is no efficient treatment for patients with metastatic breast cancer, a lack of treatment that leads to the death of 400,000
15 women worldwide per year ²⁴. Here we propose that a treatment based on inhibition of the interaction between netrin-1 and its dependence receptors could positively affect a large fractions of the patients suffering from metastatic cancer, such as breast cancer -i.e. patients who would shown high netrin-1 expression in primary tumors-. These treatments could include chemical drugs, monoclonal antibodies or the DCC-5Fbn protein presented here.

20

Example 4: Netrin-1 expression and inhibition of netrin-1 activity in other human tumors

A) Netrin-1 is a marker of aggressiveness in human neuroblastoma (see figure 9A, its legend and table 8) and inhibiting netrin-1 activity promotes neuroblastoma cell death (see
25 figure 10B ant its legend).

Table 8: 26 neuroblastoma cell lines (either obtained directly from patient tumors at Centre Léon Bérard (CLB-X) or classic neuroblastoma cell lines (IMR32, SHEP, SHSY or SKNAS)) were tested as in (a) for netrin-1 expression by Q-RT-PCR. Netrin-1 level is indicated as (-) no netrin-1, (+, ++, +++) low to high netrin-1 level. It can be noted that a

5 significant fraction of cell lines have high expression of netrin-1.

Cell line	netrin-1
CLB-BAB	-
CLB-BAC	-
CLB-BAR	-
CLB-BARREC	-
CLB-BEL	+
CLB-BOULT	++
CLB-BER2	-
CLB-BERLUD	-
CLB-CAR	-
CLB-ESP	-/+
CLB-GAR	-
CLB-GHE MO	-
CLB-GHE PCT	-
CLB-HUT	+++
CLB-MAR MO	-/+
CLB-MAR LT	+
CLB-PEC	-
CLB-REM	+++
CLB-SED	+
CLB-TRA	-
CLB-VOL	++++
IGRN91	-/+
IMR32	+++
SHEP	-/+
SHSY 5Y	-/+
SKNAS	++++

B) Netrin-1 is overexpressed in a large fraction of glioma (see figure 10A and its legend) and inhibition of netrin-1 activity promotes glioma cell death (see figure 10B and its

10 legend).

C) Netrin-1 is overexpressed in human lung cancer (see figure 11A, its legend and table 9) and inhibition of netrin-1 activity promotes lung cancer cell death and prevents lung cancer development (see figures 12C and 12D and their legends).

Table 9: Lung cancer cell lines either derived from small-cell-lung cancer (SCLC) or non-small-cell-lung cancer (NSCLC) were tested as in (a) for netrin-1 expression by Q-RT-PCR. Netrin-1 level is indicated as (-) no netrin-1, (+, ++) low to high netrin-1 level. It can be noted that a significant fraction of cell lines have high expression of netrin-1.

5

Cell line	netrin-1
NSCLC	
A549	+
H322	++
H358	++
H460	-
H1299	+
SCLC	
H69	-
H146	+
H196	-

D) Netrin-1 expression in other human tumors.

Expression of netrin-1 examined by Q-RT PCR using total RNA extracted from different human tumors as in figures 10A-10B, 11A-11C, 12A-12B. The table 10 indicates (n) the number of tumors tested and the percentage of tumors showing an overexpression of netrin-1 in each pathology.

10

Table 10:

Cancers	n	over expression of netrin-1
Renal adenocarcinoma	5	40 %
Acute myeloid leukaemia	55	62 %
Sarcoma	10	30 %
Melanoma	6	50 %
Ovarian adenocarcinoma	14	93 %*
Pancreatic adenocarcinoma	7	57 %
Uterus adenocarcinoma	42	19 %
Stomach adenocarcinoma	27	26 %
Kidney adenocarcinoma	20	50 %
Rectal adenocarcinoma	18	17 %

15 *100 % of the 7 metastatic samples

Example 5:

To analyze whether DCC was under its monomeric form unless netrin-1 was present, we transiently co-expressed an HA-tagged full-length DCC together with c-myc-tagged full-length DCC in HEK293T cells. Immunoprecipitation was then performed using an anti-c-myc antibody and as shown in figure 12A, despite a good expression of both HA and c-myc tagged-DCC, HA-DCC was only modestly included in the c-myc-DCC pull-down in absence of ligand, suggesting that DCC, was mainly present as a monomer when expressed in HEK293T in the absence of netrin-1. In the same experimental conditions, when netrin-1 was added to the culture medium (not shown and figure 15C) or when a netrin-1 expression construct was co-expressed with the DCC-expressing constructs (figure 11A), HA-DCC was clearly included in the c-myc DCC pull-down, hence demonstrating that netrin-1 triggers dimerisation or multimerization of DCC. This result is in agreement with data from Tessier-Lavigne and colleagues who first reported netrin-1-induced multimerization ⁴⁶, even though in our culture and immunoprecipitation conditions, DCC displays a modest albeit detectable level of multimerization in the absence of netrin-1. This constitutive, low multimerization level could either be attributed to the low affinity of DCC receptors for themselves in the absence of ligand or to the system used, which is based on forced expression of high levels of transmembrane receptors.

We then investigated whether the other UNC5H netrin-1 receptors share a similar behaviour. HEK293T cells were transiently transfected with an HA-tagged full-length UNC5H2 together with Flag-tagged full-length UNC5H2 in the presence or absence of netrin-1. Immunoprecipitation was then performed using an anti-FlagM2 antibody. As shown in figure 11B, the presence of netrin-1 triggers an efficient immunoprecipitation of HA-UNC5H2 with Flag-UNC5H2. Thus, while in the absence of netrin-1, DCC and UNC5H2 are mainly under monomeric forms, both DCC and UNC5H2 show an increased propensity to multimerize in the presence of netrin-1.

To determine whether netrin-1-induced multimerization is the crucial step for inhibiting DCC/UNC5H2 pro-apoptotic cell death, we developed a chimeric system in which protein dimerization can be induced by a chemical agent. This system was successfully used to show both the role of caspase-8 dimerization in caspase-8 activation ⁴⁹ and the importance of p75^{ntr}-multimerization in p75^{ntr} pro-apoptotic activity ⁴⁸. This

system is derived from the ability of the Fk1012 compound to cross-dimerize the FkBP motif. DCC and UNC5H2 intracellular domains were fused in their N-terminus to derived Fv2e FkBP motives and dimerization was induced using the AP20187 chemical compound (figure 13A). We first analyzed whether the developed system recapitulates netrin-1-induced multimerization of the UNC5H2 intracellular domain. HEK293T cells were co-transfected with an HA-tagged Fv2e-UNC5H2-IC together with c-myc-tagged Fv2e-UNC5H2-IC and co-immunoprecipitations were performed using an anti-c-myc antibody. As shown in figure 13B, without addition of AP20187, HA-Fv2e-UNC5H2-IC was barely detectable in the c-myc-Fv2e-UNC5H2-IC pull-down, hence supporting that Fv2e-UNC5H2-IC is expressed in HEK293T cells mainly as a monomer. As expected, addition of AP20187 led to the efficient pull-down of HA-Fv2e-UNC5H2-IC with c-myc-Fv2e-UNC5H2-IC. Similar results were obtained with Fv2e-DCC-IC (not shown). Thus, this dimerization system recapitulates dimerization of the intracellular domain of the netrin-1 receptors DCC and UNC5H2.

Because this chemically-inducible DCC/UNC5H2 dimerization system appears to work adequately to mimic netrin-1-induced DCC/UNC5H2 multimerization, we then assessed whether the dimerization of DCC/UNC5H2 was sufficient to inhibit DCC/UNC5H2 pro-apoptotic activity. HEK293T cells were forced to express Fv2e-DCC-IC in the presence or absence of AP20187 and cell death was assessed by trypan blue staining, as previously described, to measure DCC-induced cell death^{6, 27}. As shown in figure 14A, expression of Fv2e-DCC-IC was associated with increased cell death compared to expression of the Fv2e motives without the DCC-IC fusion. Interestingly, when AP20187 was added, cell death induced by Fv2e-DCC-IC was dramatically reduced (figure 14A). Similarly, while Fv2e-UNC5H2-IC triggers cell death (figure 14B) or caspase activation (figure 14C) when expressed in HEK293T in the absence of AP20187, the addition of the dimerizing drug is sufficient to reduce significantly Fv2e-UNC5H2-IC-induced cell death (figure 14B) or caspase activation (figure 14C). Thus, while monomeric DCC-IC and UNC5H2-IC are pro-apoptotic, the multimeric forms of DCC-IC or UNC5H2-IC no longer display pro-apoptotic activity. Therefore, the ability of netrin-1 to inhibit DCC/UNC5H2-pro-apoptotic activity is intrinsically linked to the ability of netrin-1 to

multimerize DCC or UNC5H2, as this multimerization process is sufficient to shut down DCC and UNC5H2 pro-apoptotic activity.

A tempting model would be that the monomeric form of DCC or UNC5H2 has a spatial conformation that is easily subjected to the initial caspase cleavage of the receptor's intracellular domain. On the opposite, presence of the ligand would lead to multimerization of the intracellular domain, which somehow becomes less accessible to caspase cleavage. Along this line, Arakawa and colleagues have shown that the caspase cleavage of UNC5H2 is inhibited by netrin-1 presence⁴⁷. Yet, because of technical limitations, we have failed to detect DCC or UNC5H2 cleavage in cells forced to express the Fv2e fusion proteins. An alternative model to the cleavage inhibition would be that netrin-1-induced receptor multimerization triggers a survival signal, that somehow inhibits a constitutive pro-apoptotic activity of DCC or UNC5H2 related to constitutive caspase cleavage. However, we failed to show that the known positive signalling pathways activated by DCC upon netrin-1 binding are involved in the inhibitory activity of netrin-1 on DCC pro-apoptotic activity. For example, netrin-1 induces DCC-mediated activation of ERK-1/2³, kinases known to display an anti-apoptotic effect. However, classic inhibitors of the ERK-1/2 pathway, while affecting netrin-1-induced ERK-1/2 phosphorylation, failed to block the netrin-1-inhibitory effect on DCC pro-apoptotic activity (Forcet and Mehlen, unpublished). Thus, it is probable that netrin-1-induced DCC multimerization affects DCC intracellular accessibility. However, it remains to be demonstrated whether this is a matter of simple stoichiometry, or whether the bringing closer of the extracellular domains induces a change of conformation within the intracellular compartments.

If the mechanisms underlying netrin-1-induced receptor multimerization are yet to be described, the observation that netrin-1-induced DCC/UNC5H2 multimerization is sufficient to inhibit DCC/UNC5H2-induced cell death may represent an interesting tool to turn on DCC or UNC5H2 pro-apoptotic activity in vivo, in tumors in which netrin-1 is expressed in an autocrine manner. Indeed, we have demonstrated that netrin-1 overexpression in mice gut is associated with intestinal tumor development because of apoptosis inhibition¹⁸ and we have recently observed that netrin-1 is overexpressed in the majority of human metastatic breast cancers. Moreover, the mechanism of netrin-1 overexpression appears to be an acquired selective advantage of metastatic tumor cells for

survival in settings of environmental absence of netrin-1 (see examples 2 and 3). Thus, to inhibit DCC/UNC5H dimerization would putatively represent an interesting way to trigger tumor cell apoptosis.

Along this line, the fifth fibronectin domain of DCC has been shown to be a domain of interaction with netrin-1 (figure 15A and ²¹), even though conflicting data have also been reported ⁴³. We thus first assessed whether a recombinant soluble fifth fibronectin domain of DCC (DCC-5Fbn) could bind to recombinant netrin-1. ELISA assay demonstrates that DCC-5Fbn specifically binds to netrin-1, as opposed to the extracellular domain of an unrelated receptor, IL3-R (figure 15A). The approximate K_d for DCC-5Fbn/netrin-1 was roughly estimated at 5 nM, in keeping with the order of magnitude of the described DCC/netrin-1 K_d. We next investigated whether this domain was sufficient to displace DCC/netrin-1 interaction. As shown in figure 15B, using an ELISA assay in which the extracellular domain of DCC was coated and netrin-1/DCC interaction was detected by netrin-1 immunoreactivity, we observed that, while as a positive control the complete extracellular domain of DCC (DCC-EC) was sufficient to displace DCC/netrin-1 interaction, DCC-5Fbn failed to interfere. Thus, DCC-5Fbn interacts with netrin-1 but is not sufficient to inhibit DCC/netrin-1 interaction. We next investigated whether DCC-5Fbn could influence DCC multimerization. We performed co-immunoprecipitation in HEK293T transiently transfected with HA-tagged full-length DCC together with c-myc-tagged full-length DCC in the presence or absence of netrin-1. As also described in Figure 1A, presence of netrin-1 triggers the immunoprecipitation of HA-DCC with c-myc-DCC, demonstrating netrin-1-induced DCC multimerization (figure 15C). However, when the cells incubated with netrin-1 were also simultaneously treated with DCC-5Fbn, the HA-DCC/c-myc-DCC interaction returns to netrin-1 non-treated levels. Thus, DCC-5Fbn interacts with netrin-1 in a region responsible for the netrin-1-mediated coming closer of two or more DCC molecules and is able to inhibit netrin-1-induced DCC-multimerization.

We then tested whether DCC-5Fbn could consequently trigger netrin-1 receptors-induced cell death. To this purpose, HEK293T cells were forced to express DCC in the presence or absence of netrin-1, with or without DCC-5Fbn, and cell death was determined by trypan blue exclusion assay (figure 16A). As shown in figure 16A, while DCC triggers apoptosis in the absence of netrin-1, a pro-apoptotic activity blocked by the presence of

netrin-1, the presence of DCC-5Fbn is sufficient to block the inhibitory activity of netrin-1, thus leading to DCC-induced cell death. Because the HEK293T cell system uses ectopic expression of netrin-1, we next tested DCC-5Fbn in a more biologically relevant model. We recently demonstrated that compared to non-metastatic breast cancers, the majority of human metastatic breast cancers overexpresses netrin-1. We have also shown that titrating overexpressed netrin-1 triggers tumor cell apoptosis in vitro and metastasis inhibition in mice (see Examples 2 and 3). Many breast tumor cell lines appear to express netrin-1 and we have shown that titrating netrin-1 in mice breast carcinoma 4T1 cells triggers apoptosis (see Examples 2 and 3). As shown in figure 16B, addition of DCC-5Fbn to a 4T1 cell culture is associated with increased cell death.

Taken together, we have shown here that the multimerization of the dependence receptors DCC and UNC5H is a sufficient mechanism to block their pro-apoptotic activity. Interestingly, this inhibitory mechanism appears to mirror what is observed with death receptors. Indeed, it is known that TNFr or Fas requires trimerization to induce apoptosis⁴⁵. This intrinsic difference may therefore represent an added-value for therapeutic strategies using dependence receptors. Indeed, the search of therapeutic molecules in the past has mainly led to hits that act on the inhibition of cellular processes -e.g., kinases inhibitors, IAP inhibitors- rather than activators. As a consequence, inhibition of netrin-1 receptors multimerization via the use of recombinant DCC-5Fbn or via any compound screened to interfere with receptor multimerization appears as a tempting strategy for the treatment of cancers in which netrin-1 autocrine expression has been acquired.

Here, we show that netrin-1 triggers the multimerization of both DCC and UNC5H receptors. By using a system in which dimerization is chemically-induced, we demonstrate that multimerization of the intracellular domain of netrin-1 receptors, such as DCC and UNC5H2, is the critical step to inhibit their pro-apoptotic activity. We therefore propose a model in which monomeric netrin-1-dependence receptors are pro-apoptotic, while their multimerization, induced by netrin-1, abolishes their pro-apoptotic activity. Using this property, we propose the use of a recombinant specific domain of the DCC extracellular region that (i) interacts with netrin-1 and (ii) inhibits netrin-1-induced multimerization, in order to trigger apoptosis of tumor cells.

References

1. Serafini, T. et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. *Cell* **87**, 1001-14 (1996).
2. Keino-Masu, K. et al. Deleted in Colorectal Cancer (DCC) encodes a netrin
5 receptor. *Cell* **87**, 175-85 (1996).
3. Forcet, C. et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation. *Nature* **417**, 443-7 (2002).
4. Ackerman, S. L. et al. The mouse rostral cerebellar malformation gene encodes an UNC-5-like protein. *Nature* **386**, 838-42 (1997).
- 10 5. Hong, K. et al. A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. *Cell* **97**, 927-41 (1999).
6. Mehlen, P. et al. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. *Nature* **395**, 801-4 (1998).
- 15 7. Llambi, F., Causeret, F., Bloch-Gallego, E. & Mehlen, P. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. *Embo J* **20**, 2715-22 (2001).
8. Bordeaux, M. C. et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. *Embo J* **19**, 4056-63 (2000).
9. Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M. & Cheresch, D. A.
20 Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. *J Cell Biol* **155**, 459-70 (2001).
10. Thibert, C. et al. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. *Science* **301**, 843-6 (2003).
11. Matsunaga, E. et al. RGM and its receptor neogenin regulate neuronal survival. *Nat*
25 *Cell Biol* **6**, 749-55 (2004).
12. Rabizadeh, S. et al. Induction of apoptosis by the low-affinity NGF receptor. *Science* **261**, 345-8 (1993).
13. Mehlen, P. & Thibert, C. Dependence receptors: between life and death. *Cell Mol Life Sci* **61**, 1854-66 (2004).
- 30 14. Bredesen, D. E., Mehlen, P. & Rabizadeh, S. Receptors that mediate cellular dependence. *Cell Death Differ* **12**, 1031-43 (2005).

15. Fearon, E. R. et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. *Science* **247**, 49-56 (1990).
16. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. *Cell* **87**, 159-70 (1996).
- 5 17. Thiebault, K. et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. *Proc Natl Acad Sci U S A* **100**, 4173-4178 (2003).
18. Mazelin, L. et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. *Nature* **431**, 80-4 (2004).
- 10 19. Bernet, A. et al. The netrin-1 receptor UNC5H3 is a tumor suppressor in colorectal malignancies. submitted (2007).
20. Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Cancer Res* **52**, 1399-405 (1992).
- 15 21. Geisbrecht, B. V., Dowd, K. A., Barfield, R. W., Longo, P. A. & Leahy, D. J. Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin. *J Biol Chem* **278**, 32561-8 (2003).
22. Llambi, F. et al. The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. *Embo J* **24**, 1192-201 (2005).
- 20 23. Inbal, B. et al. DAP kinase links the control of apoptosis to metastasis. *Nature* **390**, 180-4 (1997).
24. Andre, F. et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. *J Clin Oncol* **22**, 3302-8 (2004).
- 25 25. de Cremoux, P. et al. Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. *Endocr Relat Cancer* **11**, 489-95 (2004).
26. Latil, A. et al. Quantification of expression of netrins, slits and their receptors in human prostate tumors. *Int J Cancer* **103**, 306-15 (2003).
27. Forcet, C., Ye, X., Granger, L., Corset, V., Shin, H., Bredesen, D.E. and Mehlen, P. (2001) The dependence receptor DCC (deleted in colorectal cancer) defines an
- 30

- alternative mechanism for caspase activation. *Proc Natl Acad Sci U S A*, 98, 3416-3421.
28. de Kok, J. B. et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. *Lab Invest* 85, 154-9 (2005).
 - 5 29. Mehlen, P. & Fearon, E. R. Role of the dependence receptor DCC in colorectal cancer pathogenesis. *J Clin Oncol* 22, 3420-8 (2004).
 30. Stupack, D. G. et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. *Nature* 439, 95-9 (2006).
 31. Serafini, T. et al. The netrins define a family of axon outgrowth-promoting proteins homologous to *C. elegans* UNC-6. *Cell* 78, 409-24 (1994).
 - 10 32. Yebra, M. et al. Recognition of the neural chemoattractant Netrin-1 by integrins $\alpha 6 \beta 4$ and $\alpha 3 \beta 1$ regulates epithelial cell adhesion and migration. *Dev Cell* 5, 695-707 (2003).
 33. Srinivasan, K., Strickland, P., Valdes, A., Shin, G. C. & Hinck, L. Netrin-1/neogenin interaction stabilizes multipotent progenitor cap cells during mammary gland morphogenesis. *Dev Cell* 4, 371-82 (2003).
 - 15 34. Liu, Y. et al. Novel role for Netrins in regulating epithelial behavior during lung branching morphogenesis. *Curr Biol* 14, 897-905 (2004).
 35. Park, K. W. et al. The axonal attractant Netrin-1 is an angiogenic factor. *Proc Natl Acad Sci U S A* 101, 16210-5 (2004).
 - 20 36. Lu, X. et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. *Nature* 432, 179-86 (2004).
 37. Nguyen, A. & Cai, H. Netrin-1 induces angiogenesis via a DCC-dependent ERK1/2-eNOS feed-forward mechanism. *Proc Natl Acad Sci U S A* 103, 6530-5 (2006).
 - 25 38. Wilson, B. D. et al. Netrins Promote Developmental and Therapeutic Angiogenesis. *Science* (2006).
 39. Chan, S.S., Zheng, H., Su, M.W., Wilk, R., Killeen, M.T., Hedgecock, E.M. and Culotti, J.G. (1996) UNC-40, a *C. elegans* homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues. *Cell*, 87, 187-195.
 - 30

40. Ellerby, L.M., Hackam, A.S., Propp, S.S., Ellerby, H.M., Rabizadeh, S., Cashman, N.R., Trifiro, M.A., Pinsky, L., Wellington, C.L., Salvesen, G.S., Hayden, M.R. and Bredesen, D.E. (1999) Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. *J Neurochem*, 72, 185-195.
- 5 41. Fazeli, A., Dickinson, S.L., Hermiston, M.L., Tighe, R.V., Steen, R.G., Small, C.G., Stoeckli, E.T., Keino-Masu, K., Masu, M., Rayburn, H., Simons, J., Bronson, R.T., Gordon, J.I., Tessier-Lavigne, M. and Weinberg, R.A. (1997) Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. *Nature*, 386, 796-804.
42. Hedgecock, E.M., Culotti, J.G. and Hall, D.H. (1990) The unc-5, unc-6, and unc-40 genes guide circumferential migrations of pioneer axons and mesodermal cells on the epidermis in *C. elegans*. *Neuron*, 4, 61-85.
- 10 43. Kruger, R.P., Lee, J., Li, W. and Guan, K.L. (2004) Mapping netrin receptor binding reveals domains of Unc5 regulating its tyrosine phosphorylation. *J Neurosci*, 24, 10826-10834.
- 15 44. Mehlen, P. and Bredesen, D.E. (2004) The dependence receptor hypothesis. *Apoptosis*, 9, 37-49.
45. Muppidi, J.R., Tschopp, J. and Siegel, R.M. (2004) Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. *Immunity*, 21, 461-465.
- 20 46. Stein, E., Zou, Y., Poo, M. and Tessier-Lavigne, M. (2001) Binding of DCC by netrin-1 to mediate axon guidance independent of adenosine A2B receptor activation. *Science*, 291, 1976-1982.
47. Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y. and Arakawa, H. (2003) p53RDL1 regulates p53-dependent apoptosis. *Nat Cell Biol*, 5, 216-223.
- 25 48. Wang, J.J., Rabizadeh, S., Tasinato, A., Sperandio, S., Ye, X., Green, M., Assa-Munt, N., Spencer, D. and Bredesen, D.E. (2000) Dimerization-dependent block of the proapoptotic effect of p75(NTR). *J Neurosci Res*, 60, 587-593.
49. Yang, X., Chang, H.Y. and Baltimore, D. (1998) Autoproteolytic activation of procaspases by oligomerization. *Mol Cell*, 1, 319-325.
- 30 50. Mehlen P. and C. Furne (2005) Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. *Cell Mol Life Sci*. 62:2599-616.

CLAIMS

1. Method for selecting a compound for the prevention or the treatment of cancer, wherein said method comprises the following steps of:
 - 5 a) having a medium containing netrin-1, or a fragment thereof, and a netrin-1 receptor, or a fragment thereof, wherein:
 - said netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, is able to specifically interact together to form a binding pair, and/or
 - said netrin-1, or a fragment thereof, is able to induce the dimerization or
 - 10 multimerization of said netrin-1 receptor, or a fragment thereof, particularly the intracellular domain of said netrin-1 receptor;
 - b) contacting said medium with the compound to be tested;
 - c) - measuring the inhibition of the interaction between netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, and/or
 - 15 - determine whether said compound inhibit the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, particularly the dimerization of the intracellular domain of said netrin-1 receptor; and
 - d) selecting said compound if:
 - the measuring in step c) demonstrates a significantly inhibition of the interaction
 - 20 between netrin-1, or a fragment thereof, and netrin-1 receptor, or a fragment thereof, in presence of said compound, and/or
 - the determination in step c) demonstrates a significantly inhibition of the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, in presence of said compound, particularly the dimerization of the intracellular domain of said netrin-1
 - 25 receptor.
2. The method according to claim 1, wherein said cancer to be prevent or treated is a cancer wherein tumoral cells express or overexpress netrin-1.
3. The method according to claim 1 or 2, wherein said cancer to be prevent or treated is selected from the group consisting of breast cancer, colorectal cancer, lung cancer,
- 30 neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma, uterus

adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal adenocarcinoma.

4. The method according to claims 1 to 3, wherein said cancer to be prevent or treated is a metastatic cancer or an aggressive cancer.

5 5. The method according to claims 1 to 4, wherein at step a) said netrin-1 receptor is selected from the group of DCC, UNC5H (particularly UNC5H1, UNC5H2 and UNC5H3), neogenin and the adenosine A2b.

6. The method according to claim 5, wherein at step a) said netrin-1 receptor is selected from the group of DCC, UNC5H1, UNC5H2 and UNC5H3.

10 7. The method according to claims 1 to 6, wherein at step a):

- said netrin-1 receptor fragment comprises or is the extracellular domain of the netrin-1 receptor, or part thereof able to interact with netrin-1; and/or
- said netrin-1 receptor fragment comprises or is the intracellular domain of the netrin-1 receptor, or part thereof able to dimerize or multimerize in presence of netrin-1.

15 8. The method according to claims 1 to 7, wherein at step a) said netrin-1 or/and said netrin 1 receptor are from mammal, particularly from mouse, rat or human.

9. The method according to claims 1 to 8, wherein at step a) said netrin-1 is from chicken.

20 10. The method according to claims 1 to 9, wherein said netrin-1 or/and said netrin-1 receptor and/or the compound to be tested is labelled by a marker able to be directly or indirectly measured.

11. The method according to claims 1 to 10, wherein at step c):

- the measure of the inhibition of the interaction between netrin-1, or a fragment thereof, and said netrin-1 receptor, or a fragment thereof, is carried out by immunoassay (particularly by ELISA or by Immunoradiometric Assay (IRMA)), by Scintillation Proximity Assay (SPA) or by Fluorescence Resonance Energy Transfer (FRET); and/or
- the dimerization or multimerization, or its inhibition, of said netrin-1 receptor, or fragment thereof, particularly the intracellular domain, is carried out by immunoprecipitation or FRET.

30 12. The method according to claims 1 to 11, wherein at step a) said medium contains cells which express at their surface membrane an endogenous netrin-1 receptor or

a recombinant netrin-1 receptor, particularly at least the extracellular domain of a recombinant netrin-1 receptor.

13. The method according to claim 12, wherein at step a) said medium contains cells which express recombinant netrin-1 receptor.

5 14. The method according to claim 12, wherein at step a) said medium contains tumoral cells which express endogenously said netrin-1 receptor at their membrane surface and which express or overexpress netrin-1, and wherein at step c) the inhibition of the interaction between netrin-1 and its netrin-1 receptor in presence of the compound to be tested, is measured by the apoptosis or cells death induced by the presence of the compound
10 to be tested.

15. The method according to claim 14, wherein at step a) said medium contains metastatic tumoral cells, particularly cells selected from the group consisting of 4T1 cells, CAL51 cells, T47D cells, SKBR7 cells, IMR32 cells, GL26 cells and H358 cells.

16. A method according to claims 1 to 15 for selecting a compound for the
15 prevention or the treatment of cancer, wherein said method comprises the following steps of:

- a) having a medium containing a mammal cell expressing an endogenous or a recombinant netrin-1 receptor, or a fragment thereof comprising at least its intracellular domain, preferably a tumor cell, more preferably a cell presenting dimerization or multimerization
20 of its netrin-1 receptor intracellular domain or a cell wherein its netrin-1 receptor intracellular domain is able to dimerize or multimerize in presence of netrin-1;
- b) contacting said medium with the compound to be tested, optionally the medium further containing netrin-1, or a fragment thereof able to interact with the extracellular domain of the netrin-1 receptor;
- 25 c) determine whether the dimerization or multimerization of said netrin-1 receptor intracellular domain is inhibited in presence of said compound to be tested;
- d) optionally, determine whether the presence of the compound to be tested induces the cell death of said mammal cell; and
- e) selecting said compound if the determination in step c) demonstrates a significantly
30 inhibition of the dimerization or multimerization of the intracellular domain of said netrin-1

receptor and/or if the determination in step d) demonstrates the cell death of said mammal cell.

17. An *in vitro* method for predicting the presence of a metastatic or an aggressive cancer in a patient having a primary tumor from a biopsy of said patient
5 containing primary tumors cells, said method comprising the following step of:

(a) measuring of the netrin-1 expression level in said biopsy.

18. The method according to claim 17, wherein an increase of the netrin-1 expression level in said biopsy, compared with expression of netrin-1 in a non-metastatic primary tumor biopsies or in a non-aggressive cancer biopsies is significant of the presence
10 of a metastatic cancer or an aggressive cancer.

19. The method according to claims 17 and 18, wherein a ratio superior to 2 between netrin-1 expression in the biopsy to be tested and in the non-metastatic reference biopsy is significant of the presence of a metastatic cancer.

20. A method for determining *in vitro* the efficiency of an anti-cancer treatment
15 for a patient or for *in vitro* selecting patients who respond to a specific anti-cancer treatment, said method comprising the following step of:

(a) obtaining a primary tumor biopsy of said treated patient; and

(b) measuring of the netrin-1 expression level in said biopsy,

wherein the efficiency of said anti-cancer treatment is correlated with the decrease of the
20 amount of the netrin-1 expression level measured in said biopsy, or
wherein the selected patients who respond to a specific anti-cancer treatment are patients where the amount of the netrin-1 expression level measured in their biopsy has been decreased after said specific treatment.

21. A method according to claim 20, wherein said cancer induced an
25 overexpression of netrin-1 and/or is a metastatic or an aggressive cancer.

22. The method according to claims 17 to 21, wherein the measured netrin-1 expression product is the RNA encoding netrin-1, particularly measured by a quantitative real time reverse PCR method.

23. The method according to claims 17 to 21, wherein the expression level of
30 netrin-1 which is measured is the measuring of the netrin-1 protein level, particularly by a method using specific antibodies able to specifically recognize said netrin-1 protein.

24. The method according to claims 17 to 23, wherein the primary tumor is a primary tumor of a cancer selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma, uterus
 5 adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal adenocarcinoma.

25. Kit for the selection of a compound for the prevention or the treatment of cancer, wherein said kit comprises:

- a netrin-1 receptor protein, or a fragment thereof able to specifically interact with
 10 the netrin-1 protein to form a binding pair, preferably recombinant protein; and
- netrin-1 protein, or a fragment thereof able to specifically interact with said netrin-1 receptor protein to form a binding pair, preferably recombinant protein.

26. Kit for the selection of a compound for the prevention or the treatment of cancer, wherein said kit comprises:

- 15 - tumoral cells which express netrin-1 receptor and which express or overexpress netrin-1, particularly cells from tumoral cell line, preferably selected from the group consisting of 4T1 cells, CAL51 cells, T47D cells, SKBR7 cells, IMR32 cells, GL26 cells and H358 cells; and, optionally,
- netrin-1 protein, or a fragment thereof able to specifically interact with said netrin-1 receptor protein to form a binding pair, preferably a recombinant netrin-1 protein.
 20

27. A compound selected from the group consisting of:

- a compound selected by the method of claims 1 to 15;
- a compound comprising an extracellular domain of netrin-1 receptor or fragment thereof able to specifically inhibit the interaction between the netrin-1 and said netrin-1
 25 receptor, and/or able to inhibit the dimerization or multimerization of said netrin-1 receptor, or a fragment thereof, particularly the intracellular domain of said netrin-1 receptor; and
- a monoclonal or polyclonal antibody directed specifically against netrin-1 or netrin-1 receptor, particularly directed to the extracellular domain of said netrin-1 receptor or to the netrin-1 fragment able to interact with the extracellular domain of said netrin-1
 30 receptor,
 as a medicament.

28. A compound according to claim 27, wherein said extracellular domain of netrin-1 receptor or fragment thereof is selected from the group of DCC, UNC5H (particularly UNC5H1, UNC5H2 and UNC5H3), neogenin and the adenosine A2b.

29. A compound according to claim 27 or 28, wherein said compound
5 comprising an extracellular domain of netrin-1 receptor is from DCC, preferably said compound is DCC-EC-Fc or DCC-5Fbn.

30. Method of treatment for inducing the apoptosis or the cell death of tumor cells which have acquired the selective advantage to escape netrin-1 dependence receptors induced apoptosis, preferably by elevated netrin-1 level, in a patient comprising
10 administering a compound able to inhibit this selective advantage in a tumor cell in said patient in need thereof.

31. Method for the prevention or for the treatment of cancer in a patient comprising administering a compound according to claims 27 to 29 in said patient in need thereof.

15 32. Use of a compound according to claims 27 to 29 for the manufacture of a medicament for the prevention or the treatment of cancer in mammals, including man.

33. The method or the use according to claim 31 or 32, characterized in that said cancer is a metastatic or an aggressive cancer.

34. The method or the use according to claims 30 to 32, characterized in that
20 said cancer selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian adenocarcinoma, renal adenocarcinoma, pancreatic adenocarcinoma, uterus adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal adenocarcinoma.

25 35. The method or the use according to claims 29 to 34, characterized in that the primary tumor cells of said cancer express or overexpress netrin-1.

36. Use of the level of netrin-1 expression as a marker for the identification of a metastatic or an aggressive cancer in a patient.

37. Use according to claim 36, wherein said metastatic or aggressive cancer is
30 selected from the group consisting of breast cancer, colorectal cancer, lung cancer, neuroblastoma, glioma, acute myeloid leukemia, sarcoma, melanoma, ovarian

adenocarcinoma, renal adenocarcinoma pancreatic adenocarcinoma, uterus
adenocarcinoma, stomach adenocarcinoma, kidney adenocarcinoma and rectal
adenocarcinoma.